HRP20140265T1 - Derivat aminopirazina i odgovarajuä†i lijek - Google Patents
Derivat aminopirazina i odgovarajuä†i lijek Download PDFInfo
- Publication number
- HRP20140265T1 HRP20140265T1 HRP20140265AT HRP20140265T HRP20140265T1 HR P20140265 T1 HRP20140265 T1 HR P20140265T1 HR P20140265A T HRP20140265A T HR P20140265AT HR P20140265 T HRP20140265 T HR P20140265T HR P20140265 T1 HRP20140265 T1 HR P20140265T1
- Authority
- HR
- Croatia
- Prior art keywords
- fluorophenyl
- pyrazin
- ylamino
- ethylamino
- pyrimidin
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- XFTQRUTUGRCSGO-UHFFFAOYSA-N pyrazin-2-amine Chemical class NC1=CN=CC=N1 XFTQRUTUGRCSGO-UHFFFAOYSA-N 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 claims 50
- 125000000753 cycloalkyl group Chemical group 0.000 claims 24
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 23
- 125000003545 alkoxy group Chemical group 0.000 claims 22
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims 20
- 229920006395 saturated elastomer Chemical group 0.000 claims 19
- 125000003277 amino group Chemical group 0.000 claims 17
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 15
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 15
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 13
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 13
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 13
- 229910052736 halogen Inorganic materials 0.000 claims 12
- 150000002367 halogens Chemical class 0.000 claims 12
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 11
- 125000004093 cyano group Chemical group *C#N 0.000 claims 10
- -1 hydroxy, amino Chemical group 0.000 claims 10
- 239000000825 pharmaceutical preparation Substances 0.000 claims 10
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 9
- 125000004663 dialkyl amino group Chemical group 0.000 claims 9
- 125000001072 heteroaryl group Chemical group 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims 8
- 125000003282 alkyl amino group Chemical group 0.000 claims 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 6
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 6
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 6
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 5
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims 5
- 125000001188 haloalkyl group Chemical group 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 4
- 208000035269 cancer or benign tumor Diseases 0.000 claims 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 4
- 230000002062 proliferating effect Effects 0.000 claims 4
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 3
- 125000006310 cycloalkyl amino group Chemical group 0.000 claims 3
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims 3
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 claims 3
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 claims 2
- 206010059245 Angiopathy Diseases 0.000 claims 2
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims 2
- 201000005787 hematologic cancer Diseases 0.000 claims 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- FJCWZFGMTGFDBJ-WBAXXEDZSA-N (1s,2s)-2-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]oxycyclohexan-1-ol Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(O[C@@H]1[C@H](CCCC1)O)C=1)=NC=1NC1=CN=CC=N1 FJCWZFGMTGFDBJ-WBAXXEDZSA-N 0.000 claims 1
- DKKLNNFJNWZTJD-MAUKXSAKSA-N (2r)-2-[[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]amino]-4-methylpentan-1-ol Chemical compound N=1C(N[C@@H](C)C=2C=CC(F)=CC=2)=NC(N[C@@H](CO)CC(C)C)=CC=1NC1=CN=CC=N1 DKKLNNFJNWZTJD-MAUKXSAKSA-N 0.000 claims 1
- NZJCPQZFYBUJBZ-BBRMVZONSA-N (2s)-1-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]pyrrolidine-2-carboxamide Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)N2[C@@H](CCC2)C(N)=O)=NC=1NC1=CN=CC=N1 NZJCPQZFYBUJBZ-BBRMVZONSA-N 0.000 claims 1
- AFXKWISTRWZCPY-OXJNMPFZSA-N (2s)-2-[[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]amino]-2-phenylethanol Chemical compound C1([C@@H](CO)NC=2N=C(N=C(NC=3N=CC=NC=3)C=2)N[C@@H](C)C=2C=CC(F)=CC=2)=CC=CC=C1 AFXKWISTRWZCPY-OXJNMPFZSA-N 0.000 claims 1
- KQZNYKWIHNWWOJ-FZMZJTMJSA-N (2s)-2-[[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]amino]-3-hydroxypropanamide Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=NC(N[C@@H](CO)C(N)=O)=CC=1NC1=CN=CC=N1 KQZNYKWIHNWWOJ-FZMZJTMJSA-N 0.000 claims 1
- QLVBFEIFEVJWLM-WMLDXEAASA-N (2s)-2-[[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]amino]-3-methylbutan-1-ol Chemical compound N=1C(N[C@@H](C)C=2C=CC(F)=CC=2)=NC(N[C@H](CO)C(C)C)=CC=1NC1=CN=CC=N1 QLVBFEIFEVJWLM-WMLDXEAASA-N 0.000 claims 1
- IIQPKDTURMWWTF-UWJYYQICSA-N (2s)-2-[[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]amino]-3-phenylpropan-1-ol Chemical compound C([C@@H](CO)NC=1N=C(N=C(NC=2N=CC=NC=2)C=1)N[C@@H](C)C=1C=CC(F)=CC=1)C1=CC=CC=C1 IIQPKDTURMWWTF-UWJYYQICSA-N 0.000 claims 1
- XCAOBNHVHONKOJ-RCBQFDQVSA-N (3s,4s)-1-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]pyrrolidine-3,4-diol Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)N2C[C@H](O)[C@@H](O)C2)=NC=1NC1=CN=CC=N1 XCAOBNHVHONKOJ-RCBQFDQVSA-N 0.000 claims 1
- IWJUJXLBOSIZLI-SWLSCSKDSA-N (4r)-1-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]-4-hydroxypyrrolidin-2-one Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)N2C(C[C@@H](O)C2)=O)=NC=1NC1=CN=CC=N1 IWJUJXLBOSIZLI-SWLSCSKDSA-N 0.000 claims 1
- QGCLEUGNYRXBMZ-UHFFFAOYSA-N 1-(4-fluorophenyl)ethanamine Chemical compound CC(N)C1=CC=C(F)C=C1 QGCLEUGNYRXBMZ-UHFFFAOYSA-N 0.000 claims 1
- NOYMVIJRKIIOIR-AWEZNQCLSA-N 1-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyridin-4-yl]-3-methylazetidin-3-ol Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=CC(N2CC(C)(O)C2)=CC=1NC1=CN=CC=N1 NOYMVIJRKIIOIR-AWEZNQCLSA-N 0.000 claims 1
- UDJCEYQBVTVROD-INIZCTEOSA-N 1-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyridin-4-yl]-3-propan-2-ylazetidin-3-ol Chemical compound C1C(C(C)C)(O)CN1C1=CC(N[C@@H](C)C=2C=CC(F)=CC=2)=NC(NC=2N=CC=NC=2)=C1 UDJCEYQBVTVROD-INIZCTEOSA-N 0.000 claims 1
- FWNKWBMHUGLMAG-INIZCTEOSA-N 1-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyridin-4-yl]-4-(hydroxymethyl)piperidin-4-ol Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=CC(N2CCC(O)(CO)CC2)=CC=1NC1=CN=CC=N1 FWNKWBMHUGLMAG-INIZCTEOSA-N 0.000 claims 1
- CBDSFLQURXHATM-ZDUSSCGKSA-N 1-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyridin-4-yl]azetidin-3-ol Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=CC(N2CC(O)C2)=CC=1NC1=CN=CC=N1 CBDSFLQURXHATM-ZDUSSCGKSA-N 0.000 claims 1
- ZURDPWAROMTFJD-LBPRGKRZSA-N 1-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyridin-4-yl]ethanone Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=CC(C(C)=O)=CC=1NC1=CN=CC=N1 ZURDPWAROMTFJD-LBPRGKRZSA-N 0.000 claims 1
- CXQCDZZRVLJCPA-HNNXBMFYSA-N 1-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyridin-4-yl]piperidin-4-ol Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=CC(N2CCC(O)CC2)=CC=1NC1=CN=CC=N1 CXQCDZZRVLJCPA-HNNXBMFYSA-N 0.000 claims 1
- VGKLFRFXSJOZJG-ZDUSSCGKSA-N 1-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]-1,3-diazinan-2-one Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)N2C(NCCC2)=O)=NC=1NC1=CN=CC=N1 VGKLFRFXSJOZJG-ZDUSSCGKSA-N 0.000 claims 1
- ODRAVSXLFSHLGY-LBPRGKRZSA-N 1-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]-3-(trifluoromethyl)azetidin-3-ol Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)N2CC(O)(C2)C(F)(F)F)=NC=1NC1=CN=CC=N1 ODRAVSXLFSHLGY-LBPRGKRZSA-N 0.000 claims 1
- XTIMGPZMDQTAQB-ZDUSSCGKSA-N 1-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]-3-methylazetidin-3-ol Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)N2CC(C)(O)C2)=NC=1NC1=CN=CC=N1 XTIMGPZMDQTAQB-ZDUSSCGKSA-N 0.000 claims 1
- AOVZMFSULDEASS-HNNXBMFYSA-N 1-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]-3-propan-2-ylazetidin-3-ol Chemical compound C1C(C(C)C)(O)CN1C1=CC(NC=2N=CC=NC=2)=NC(N[C@@H](C)C=2C=CC(F)=CC=2)=N1 AOVZMFSULDEASS-HNNXBMFYSA-N 0.000 claims 1
- MLMWPPPFFAOMDB-AWEZNQCLSA-N 1-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]-n,n-dimethylazetidine-3-carboxamide Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)N2CC(C2)C(=O)N(C)C)=NC=1NC1=CN=CC=N1 MLMWPPPFFAOMDB-AWEZNQCLSA-N 0.000 claims 1
- WCJNTOYFCCWLIM-AWEZNQCLSA-N 1-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]-n-(2-hydroxyethyl)azetidine-3-carboxamide Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)N2CC(C2)C(=O)NCCO)=NC=1NC1=CN=CC=N1 WCJNTOYFCCWLIM-AWEZNQCLSA-N 0.000 claims 1
- AKRPCKBUOUEKFD-HNNXBMFYSA-N 1-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]-n-(2-methoxyethyl)azetidine-3-carboxamide Chemical compound C1C(C(=O)NCCOC)CN1C1=CC(NC=2N=CC=NC=2)=NC(N[C@@H](C)C=2C=CC(F)=CC=2)=N1 AKRPCKBUOUEKFD-HNNXBMFYSA-N 0.000 claims 1
- QMQCYOLFWWFLEN-ZDUSSCGKSA-N 1-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]-n-methylazetidine-3-carboxamide Chemical compound C1C(C(=O)NC)CN1C1=CC(NC=2N=CC=NC=2)=NC(N[C@@H](C)C=2C=CC(F)=CC=2)=N1 QMQCYOLFWWFLEN-ZDUSSCGKSA-N 0.000 claims 1
- OUZVIEZAMSUOHU-HNNXBMFYSA-N 1-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]-n-methylsulfonylpiperidine-4-carboxamide Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)N2CCC(CC2)C(=O)NS(C)(=O)=O)=NC=1NC1=CN=CC=N1 OUZVIEZAMSUOHU-HNNXBMFYSA-N 0.000 claims 1
- SGXLDRBTAFRPRG-HNNXBMFYSA-N 1-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]-n-propan-2-ylazetidine-3-carboxamide Chemical compound C1C(C(=O)NC(C)C)CN1C1=CC(NC=2N=CC=NC=2)=NC(N[C@@H](C)C=2C=CC(F)=CC=2)=N1 SGXLDRBTAFRPRG-HNNXBMFYSA-N 0.000 claims 1
- FWNYUNXBAAJGGS-LBPRGKRZSA-N 1-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]azetidin-2-one Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)N2C(CC2)=O)=NC=1NC1=CN=CC=N1 FWNYUNXBAAJGGS-LBPRGKRZSA-N 0.000 claims 1
- PCJCZCBBTWBZEB-LBPRGKRZSA-N 1-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]azetidin-3-ol Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)N2CC(O)C2)=NC=1NC1=CN=CC=N1 PCJCZCBBTWBZEB-LBPRGKRZSA-N 0.000 claims 1
- HOQBUDGCSRGGBL-ZDUSSCGKSA-N 1-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]azetidine-3-carbonitrile Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)N2CC(C2)C#N)=NC=1NC1=CN=CC=N1 HOQBUDGCSRGGBL-ZDUSSCGKSA-N 0.000 claims 1
- IIDUAVZJGKCPDA-LBPRGKRZSA-N 1-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]azetidine-3-carboxamide Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)N2CC(C2)C(N)=O)=NC=1NC1=CN=CC=N1 IIDUAVZJGKCPDA-LBPRGKRZSA-N 0.000 claims 1
- XIKUBFZCKKMLMC-LBPRGKRZSA-N 1-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]imidazolidin-2-one Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)N2C(NCC2)=O)=NC=1NC1=CN=CC=N1 XIKUBFZCKKMLMC-LBPRGKRZSA-N 0.000 claims 1
- STQWNRIGUSGVCZ-MBIQTGHCSA-N 1-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]piperidin-3-ol Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)N2CC(O)CCC2)=NC=1NC1=CN=CC=N1 STQWNRIGUSGVCZ-MBIQTGHCSA-N 0.000 claims 1
- KQUCXEVZUGLCLO-AWEZNQCLSA-N 1-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]piperidin-4-ol Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)N2CCC(O)CC2)=NC=1NC1=CN=CC=N1 KQUCXEVZUGLCLO-AWEZNQCLSA-N 0.000 claims 1
- QZHONNDXFJMOBB-LBAUFKAWSA-N 1-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]piperidine-3-carboxamide Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)N2CC(CCC2)C(N)=O)=NC=1NC1=CN=CC=N1 QZHONNDXFJMOBB-LBAUFKAWSA-N 0.000 claims 1
- CGUUVRZVEMCCAH-AWEZNQCLSA-N 1-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]piperidine-4-carboxylic acid Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)N2CCC(CC2)C(O)=O)=NC=1NC1=CN=CC=N1 CGUUVRZVEMCCAH-AWEZNQCLSA-N 0.000 claims 1
- SGJPQJXDJVJPPS-LBPRGKRZSA-N 1-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]pyrazole-4-carboxylic acid Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)N2N=CC(=C2)C(O)=O)=NC=1NC1=CN=CC=N1 SGJPQJXDJVJPPS-LBPRGKRZSA-N 0.000 claims 1
- SCVPFKWGRMPVIL-KNVGNIICSA-N 1-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]pyrrolidin-3-ol Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)N2CC(O)CC2)=NC=1NC1=CN=CC=N1 SCVPFKWGRMPVIL-KNVGNIICSA-N 0.000 claims 1
- MOQKHLVCLJHRKD-KRWDZBQOSA-N 1-[4-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyridin-4-yl]-1,4-diazepan-1-yl]ethanone Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=CC(N2CCN(CCC2)C(C)=O)=CC=1NC1=CN=CC=N1 MOQKHLVCLJHRKD-KRWDZBQOSA-N 0.000 claims 1
- LKDNYRGOICVSCG-UHFFFAOYSA-N 2-(4-fluorophenyl)-2-[[4-(1-methylpyrazol-4-yl)-6-(pyrazin-2-ylamino)pyridin-2-yl]amino]ethanol Chemical compound C1=NN(C)C=C1C1=CC(NC(CO)C=2C=CC(F)=CC=2)=NC(NC=2N=CC=NC=2)=C1 LKDNYRGOICVSCG-UHFFFAOYSA-N 0.000 claims 1
- NLNPXMGJGAXYLU-LYKKTTPLSA-N 2-N-[1-(4-fluorophenyl)ethyl]-6-N-pyrazin-2-yl-4-N-[(1S)-1-pyridin-3-ylethyl]pyrimidine-2,4,6-triamine Chemical compound FC1=CC=C(C=C1)C(C)NC1=NC(=CC(=N1)NC1=NC=CN=C1)N[C@@H](C)C=1C=NC=CC1 NLNPXMGJGAXYLU-LYKKTTPLSA-N 0.000 claims 1
- LWPASYMORFEOKT-ZDUSSCGKSA-N 2-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyridin-4-yl]oxyethanol Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=CC(OCCO)=CC=1NC1=CN=CC=N1 LWPASYMORFEOKT-ZDUSSCGKSA-N 0.000 claims 1
- YUVZOPFZMDUFIV-LBPRGKRZSA-N 2-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]oxyethanol Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(OCCO)C=1)=NC=1NC1=CN=CC=N1 YUVZOPFZMDUFIV-LBPRGKRZSA-N 0.000 claims 1
- VMFPEXBZVUCQIV-LBPRGKRZSA-N 2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)-n-(2,2,2-trifluoroethyl)pyridine-4-carboxamide Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=CC(C(=O)NCC(F)(F)F)=CC=1NC1=CN=CC=N1 VMFPEXBZVUCQIV-LBPRGKRZSA-N 0.000 claims 1
- CGVTZFDLSXQMNL-NSHDSACASA-N 2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyridine-3-carboxamide Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(C(=CC=1)C(N)=O)=NC=1NC1=CN=CC=N1 CGVTZFDLSXQMNL-NSHDSACASA-N 0.000 claims 1
- COVOVZDAFSSSIJ-LBPRGKRZSA-N 2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyridine-4-carbonitrile Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=CC(C#N)=CC=1NC1=CN=CC=N1 COVOVZDAFSSSIJ-LBPRGKRZSA-N 0.000 claims 1
- MDNACEJOJJHXMN-NSHDSACASA-N 2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyridine-4-carboxamide Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=CC(C(N)=O)=CC=1NC1=CN=CC=N1 MDNACEJOJJHXMN-NSHDSACASA-N 0.000 claims 1
- BKDJJUNQTIRGHI-NSHDSACASA-N 2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyridine-4-carboxylic acid Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=CC(C(O)=O)=CC=1NC1=CN=CC=N1 BKDJJUNQTIRGHI-NSHDSACASA-N 0.000 claims 1
- LWBGGUWQTRBGOH-NSHDSACASA-N 2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidine-4-carbonitrile Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)C#N)=NC=1NC1=CN=CC=N1 LWBGGUWQTRBGOH-NSHDSACASA-N 0.000 claims 1
- ZGGUFAJGGUXTGC-ZDUSSCGKSA-N 2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-n,n-dimethyl-6-(pyrazin-2-ylamino)pyridine-3-carboxamide Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(C(=CC=1)C(=O)N(C)C)=NC=1NC1=CN=CC=N1 ZGGUFAJGGUXTGC-ZDUSSCGKSA-N 0.000 claims 1
- ZZJFAVYORDRWFR-ZDUSSCGKSA-N 2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-n,n-dimethyl-6-(pyrazin-2-ylamino)pyridine-4-carboxamide Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=CC(C(=O)N(C)C)=CC=1NC1=CN=CC=N1 ZZJFAVYORDRWFR-ZDUSSCGKSA-N 0.000 claims 1
- YQGRYEFZAFUANB-ZDUSSCGKSA-N 2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-n-(2-hydroxyethyl)-6-(pyrazin-2-ylamino)pyridine-4-carboxamide Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=CC(C(=O)NCCO)=CC=1NC1=CN=CC=N1 YQGRYEFZAFUANB-ZDUSSCGKSA-N 0.000 claims 1
- MTBVRISBMIHPQV-AWEZNQCLSA-N 2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-n-(2-methoxyethyl)-6-(pyrazin-2-ylamino)pyridine-4-carboxamide Chemical compound C1([C@H](C)NC=2C=C(C=C(NC=3N=CC=NC=3)N=2)C(=O)NCCOC)=CC=C(F)C=C1 MTBVRISBMIHPQV-AWEZNQCLSA-N 0.000 claims 1
- QFDNQYIZRBLVGI-HNNXBMFYSA-N 2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-n-(2-methylpropyl)-6-(pyrazin-2-ylamino)pyridine-4-carboxamide Chemical compound C1([C@H](C)NC=2C=C(C=C(NC=3N=CC=NC=3)N=2)C(=O)NCC(C)C)=CC=C(F)C=C1 QFDNQYIZRBLVGI-HNNXBMFYSA-N 0.000 claims 1
- ADCHOZWPLRCZND-AWEZNQCLSA-N 2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-n-(3-hydroxypropyl)-6-(pyrazin-2-ylamino)pyridine-4-carboxamide Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=CC(C(=O)NCCCO)=CC=1NC1=CN=CC=N1 ADCHOZWPLRCZND-AWEZNQCLSA-N 0.000 claims 1
- XZNPNBFCUUXBGM-LBPRGKRZSA-N 2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-n-methyl-6-(pyrazin-2-ylamino)pyridine-3-carboxamide Chemical compound N1=C(N[C@@H](C)C=2C=CC(F)=CC=2)C(C(=O)NC)=CC=C1NC1=CN=CC=N1 XZNPNBFCUUXBGM-LBPRGKRZSA-N 0.000 claims 1
- AVFBCLOBVSZXPF-LBPRGKRZSA-N 2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-n-methyl-6-(pyrazin-2-ylamino)pyridine-4-carboxamide Chemical compound C1([C@H](C)NC=2C=C(C=C(NC=3N=CC=NC=3)N=2)C(=O)NC)=CC=C(F)C=C1 AVFBCLOBVSZXPF-LBPRGKRZSA-N 0.000 claims 1
- JEOROSBTXYBNQP-AWEZNQCLSA-N 2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-n-propan-2-yl-6-(pyrazin-2-ylamino)pyridine-4-carboxamide Chemical compound C1([C@H](C)NC=2C=C(C=C(NC=3N=CC=NC=3)N=2)C(=O)NC(C)C)=CC=C(F)C=C1 JEOROSBTXYBNQP-AWEZNQCLSA-N 0.000 claims 1
- HHCUQVQMPXUYLZ-AWEZNQCLSA-N 2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-n-propyl-6-(pyrazin-2-ylamino)pyridine-4-carboxamide Chemical compound C1([C@H](C)NC=2C=C(C=C(NC=3N=CC=NC=3)N=2)C(=O)NCCC)=CC=C(F)C=C1 HHCUQVQMPXUYLZ-AWEZNQCLSA-N 0.000 claims 1
- GBCDOFGGYKTGMP-AWEZNQCLSA-N 2-[[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]-(2-hydroxyethyl)amino]ethanol Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)N(CCO)CCO)=NC=1NC1=CN=CC=N1 GBCDOFGGYKTGMP-AWEZNQCLSA-N 0.000 claims 1
- LIAJMCIZDLLFMJ-HNNXBMFYSA-N 2-n-[(1s)-1-(4-chlorophenyl)ethyl]-6-(4-methylsulfonylpiperazin-1-yl)-4-n-pyrazin-2-ylpyrimidine-2,4-diamine Chemical compound N([C@@H](C)C=1C=CC(Cl)=CC=1)C(N=C(C=1)N2CCN(CC2)S(C)(=O)=O)=NC=1NC1=CN=CC=N1 LIAJMCIZDLLFMJ-HNNXBMFYSA-N 0.000 claims 1
- QFCGJLLVHUXLRF-ZDUSSCGKSA-N 2-n-[(1s)-1-(4-fluorophenyl)ethyl]-4-n-(5-methyl-1,3-thiazol-2-yl)-6-n-pyrazin-2-ylpyrimidine-2,4,6-triamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(NC=1N=CC=NC=1)C=1)=NC=1NC1=NC=C(C)S1 QFCGJLLVHUXLRF-ZDUSSCGKSA-N 0.000 claims 1
- QSNMJLYBEKHNBF-HNNXBMFYSA-N 2-n-[(1s)-1-(4-fluorophenyl)ethyl]-4-n-[(5-methylpyrazin-2-yl)methyl]-6-n-pyrazin-2-ylpyrimidine-2,4,6-triamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(NC=1N=CC=NC=1)C=1)=NC=1NCC1=CN=C(C)C=N1 QSNMJLYBEKHNBF-HNNXBMFYSA-N 0.000 claims 1
- AKURXXAIXQRPFJ-LBPRGKRZSA-N 2-n-[(1s)-1-(4-fluorophenyl)ethyl]-4-n-pyrazin-2-yl-6-(1,3-thiazol-2-yl)pyrimidine-2,4-diamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)C=2SC=CN=2)=NC=1NC1=CN=CC=N1 AKURXXAIXQRPFJ-LBPRGKRZSA-N 0.000 claims 1
- RQCJGWPCGQOTPQ-LBPRGKRZSA-N 2-n-[(1s)-1-(4-fluorophenyl)ethyl]-4-n-pyrazin-2-yl-6-(1,3-thiazol-5-yl)pyrimidine-2,4-diamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)C=2SC=NC=2)=NC=1NC1=CN=CC=N1 RQCJGWPCGQOTPQ-LBPRGKRZSA-N 0.000 claims 1
- RSNWFMVKIGCTMU-LBPRGKRZSA-N 2-n-[(1s)-1-(4-fluorophenyl)ethyl]-4-n-pyrazin-2-yl-6-(1h-pyrazol-4-yl)pyrimidine-2,4-diamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)C2=CNN=C2)=NC=1NC1=CN=CC=N1 RSNWFMVKIGCTMU-LBPRGKRZSA-N 0.000 claims 1
- JXQLLFDFRXUSCN-LBPRGKRZSA-N 2-n-[(1s)-1-(4-fluorophenyl)ethyl]-4-n-pyrazin-2-yl-6-(1h-pyrazol-5-yl)pyrimidine-2,4-diamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)C2=NNC=C2)=NC=1NC1=CN=CC=N1 JXQLLFDFRXUSCN-LBPRGKRZSA-N 0.000 claims 1
- ITLFJMCGZUHUBD-JTQLQIEISA-N 2-n-[(1s)-1-(4-fluorophenyl)ethyl]-4-n-pyrazin-2-yl-6-(2h-tetrazol-5-yl)pyrimidine-2,4-diamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)C2=NNN=N2)=NC=1NC1=CN=CC=N1 ITLFJMCGZUHUBD-JTQLQIEISA-N 0.000 claims 1
- PVEWZRQDTRDQKC-INIZCTEOSA-N 2-n-[(1s)-1-(4-fluorophenyl)ethyl]-4-n-pyrazin-2-yl-6-(3-pyrrolidin-1-ylazetidin-1-yl)pyrimidine-2,4-diamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)N2CC(C2)N2CCCC2)=NC=1NC1=CN=CC=N1 PVEWZRQDTRDQKC-INIZCTEOSA-N 0.000 claims 1
- UGURFRYYADUQLY-HNNXBMFYSA-N 2-n-[(1s)-1-(4-fluorophenyl)ethyl]-4-n-pyrazin-2-yl-6-n-(pyridin-2-ylmethyl)pyrimidine-2,4,6-triamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(NC=1N=CC=NC=1)C=1)=NC=1NCC1=CC=CC=N1 UGURFRYYADUQLY-HNNXBMFYSA-N 0.000 claims 1
- IORPLFMONAYHKG-HNNXBMFYSA-N 2-n-[(1s)-1-(4-fluorophenyl)ethyl]-4-n-pyrazin-2-yl-6-n-(pyridin-3-ylmethyl)pyrimidine-2,4,6-triamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(NC=1N=CC=NC=1)C=1)=NC=1NCC1=CC=CN=C1 IORPLFMONAYHKG-HNNXBMFYSA-N 0.000 claims 1
- UWLNXNQQCHAAIM-HNNXBMFYSA-N 2-n-[(1s)-1-(4-fluorophenyl)ethyl]-4-n-pyrazin-2-yl-6-n-(pyridin-4-ylmethyl)pyrimidine-2,4,6-triamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(NC=1N=CC=NC=1)C=1)=NC=1NCC1=CC=NC=C1 UWLNXNQQCHAAIM-HNNXBMFYSA-N 0.000 claims 1
- IAXYONBBKSZJPZ-AWEZNQCLSA-N 2-n-[(1s)-1-(4-fluorophenyl)ethyl]-4-n-pyrazin-2-yl-6-pyridin-2-ylpyrimidine-2,4-diamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)C=2N=CC=CC=2)=NC=1NC1=CN=CC=N1 IAXYONBBKSZJPZ-AWEZNQCLSA-N 0.000 claims 1
- KGDFJWVFSJPHBU-AWEZNQCLSA-N 2-n-[(1s)-1-(4-fluorophenyl)ethyl]-4-n-pyrazin-2-yl-6-pyridin-3-ylpyrimidine-2,4-diamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)C=2C=NC=CC=2)=NC=1NC1=CN=CC=N1 KGDFJWVFSJPHBU-AWEZNQCLSA-N 0.000 claims 1
- DLJIAHFGIQTJAP-ZDUSSCGKSA-N 2-n-[(1s)-1-(4-fluorophenyl)ethyl]-4-n-pyrazin-2-yl-6-pyrimidin-5-ylpyrimidine-2,4-diamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)C=2C=NC=NC=2)=NC=1NC1=CN=CC=N1 DLJIAHFGIQTJAP-ZDUSSCGKSA-N 0.000 claims 1
- KEHGWHSICQRMLG-AWEZNQCLSA-N 2-n-[(1s)-1-(4-fluorophenyl)ethyl]-4-n-pyrazin-2-yl-6-pyrrolidin-1-ylpyrimidine-2,4-diamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)N2CCCC2)=NC=1NC1=CN=CC=N1 KEHGWHSICQRMLG-AWEZNQCLSA-N 0.000 claims 1
- GSJHPCXRYDXCLL-NSHDSACASA-N 2-n-[(1s)-1-(4-fluorophenyl)ethyl]-6-(1,2,4-oxadiazol-3-yl)-4-n-pyrazin-2-ylpyrimidine-2,4-diamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)C2=NOC=N2)=NC=1NC1=CN=CC=N1 GSJHPCXRYDXCLL-NSHDSACASA-N 0.000 claims 1
- HFONCUIJJLPYDA-LBPRGKRZSA-N 2-n-[(1s)-1-(4-fluorophenyl)ethyl]-6-(1,3-oxazol-5-yl)-4-n-pyrazin-2-ylpyrimidine-2,4-diamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)C=2OC=NC=2)=NC=1NC1=CN=CC=N1 HFONCUIJJLPYDA-LBPRGKRZSA-N 0.000 claims 1
- ZGYNUKLXCLKCCV-ZDUSSCGKSA-N 2-n-[(1s)-1-(4-fluorophenyl)ethyl]-6-(2-fluoropyridin-4-yl)-4-n-pyrazin-2-ylpyrimidine-2,4-diamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)C=2C=C(F)N=CC=2)=NC=1NC1=CN=CC=N1 ZGYNUKLXCLKCCV-ZDUSSCGKSA-N 0.000 claims 1
- IAFDACXSEPBUDQ-LBPRGKRZSA-N 2-n-[(1s)-1-(4-fluorophenyl)ethyl]-6-(2-methoxy-1,3-thiazol-5-yl)-4-n-pyrazin-2-ylpyrimidine-2,4-diamine Chemical compound S1C(OC)=NC=C1C1=CC(NC=2N=CC=NC=2)=NC(N[C@@H](C)C=2C=CC(F)=CC=2)=N1 IAFDACXSEPBUDQ-LBPRGKRZSA-N 0.000 claims 1
- YERWUPYQNBAXKJ-ZDUSSCGKSA-N 2-n-[(1s)-1-(4-fluorophenyl)ethyl]-6-(3-methoxyazetidin-1-yl)-4-n-pyrazin-2-ylpyrimidine-2,4-diamine Chemical compound C1C(OC)CN1C1=CC(NC=2N=CC=NC=2)=NC(N[C@@H](C)C=2C=CC(F)=CC=2)=N1 YERWUPYQNBAXKJ-ZDUSSCGKSA-N 0.000 claims 1
- NISBWLMAAFHZKI-INIZCTEOSA-N 2-n-[(1s)-1-(4-fluorophenyl)ethyl]-6-(3-morpholin-4-ylazetidin-1-yl)-4-n-pyrazin-2-ylpyrimidine-2,4-diamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)N2CC(C2)N2CCOCC2)=NC=1NC1=CN=CC=N1 NISBWLMAAFHZKI-INIZCTEOSA-N 0.000 claims 1
- WKRXAKKHOISUHP-AWEZNQCLSA-N 2-n-[(1s)-1-(4-fluorophenyl)ethyl]-6-(4-methylimidazol-1-yl)-4-n-pyrazin-2-ylpyrimidine-2,4-diamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)N2C=C(C)N=C2)=NC=1NC1=CN=CC=N1 WKRXAKKHOISUHP-AWEZNQCLSA-N 0.000 claims 1
- MIWDTPPANODLQK-HNNXBMFYSA-N 2-n-[(1s)-1-(4-fluorophenyl)ethyl]-6-(4-methylsulfonylphenyl)-4-n-pyrazin-2-ylpyrimidine-2,4-diamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)C=2C=CC(=CC=2)S(C)(=O)=O)=NC=1NC1=CN=CC=N1 MIWDTPPANODLQK-HNNXBMFYSA-N 0.000 claims 1
- ZTHVUKKMSYGGNK-HNNXBMFYSA-N 2-n-[(1s)-1-(4-fluorophenyl)ethyl]-6-(4-methylsulfonylpiperazin-1-yl)-4-n-pyrazin-2-ylpyrimidine-2,4-diamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)N2CCN(CC2)S(C)(=O)=O)=NC=1NC1=CN=CC=N1 ZTHVUKKMSYGGNK-HNNXBMFYSA-N 0.000 claims 1
- IRMHVBZPRJUCCV-AWEZNQCLSA-N 2-n-[(1s)-1-(4-fluorophenyl)ethyl]-6-(6-methoxypyridin-3-yl)-4-n-pyrazin-2-ylpyrimidine-2,4-diamine Chemical compound C1=NC(OC)=CC=C1C1=CC(NC=2N=CC=NC=2)=NC(N[C@@H](C)C=2C=CC(F)=CC=2)=N1 IRMHVBZPRJUCCV-AWEZNQCLSA-N 0.000 claims 1
- BIPPBKCUVIOAJZ-ZDUSSCGKSA-N 2-n-[(1s)-1-(4-fluorophenyl)ethyl]-6-(furan-3-yl)-4-n-pyrazin-2-ylpyrimidine-2,4-diamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)C2=COC=C2)=NC=1NC1=CN=CC=N1 BIPPBKCUVIOAJZ-ZDUSSCGKSA-N 0.000 claims 1
- GFJWCKIZZCJMCP-MBIQTGHCSA-N 2-n-[(1s)-1-(4-fluorophenyl)ethyl]-6-(oxolan-2-ylmethoxy)-4-n-pyrazin-2-ylpyrimidine-2,4-diamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(OCC1OCCC1)C=1)=NC=1NC1=CN=CC=N1 GFJWCKIZZCJMCP-MBIQTGHCSA-N 0.000 claims 1
- CIJKHOFHPUGSJO-KRWDZBQOSA-N 2-n-[(1s)-1-(4-fluorophenyl)ethyl]-6-[3-(4-methylpiperazin-1-yl)azetidin-1-yl]-4-n-pyrazin-2-ylpyrimidine-2,4-diamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)N2CC(C2)N2CCN(C)CC2)=NC=1NC1=CN=CC=N1 CIJKHOFHPUGSJO-KRWDZBQOSA-N 0.000 claims 1
- WFPLNKTWZCNTBR-ZDUSSCGKSA-N 2-n-[(1s)-1-(4-fluorophenyl)ethyl]-6-[3-(methylamino)azetidin-1-yl]-4-n-pyrazin-2-ylpyrimidine-2,4-diamine Chemical compound C1C(NC)CN1C1=CC(NC=2N=CC=NC=2)=NC(N[C@@H](C)C=2C=CC(F)=CC=2)=N1 WFPLNKTWZCNTBR-ZDUSSCGKSA-N 0.000 claims 1
- CSONLROZPLBDOA-MBIQTGHCSA-N 2-n-[(1s)-1-(4-fluorophenyl)ethyl]-6-n-(oxolan-2-ylmethyl)-4-n-pyrazin-2-ylpyrimidine-2,4,6-triamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(NC=1N=CC=NC=1)C=1)=NC=1NCC1CCCO1 CSONLROZPLBDOA-MBIQTGHCSA-N 0.000 claims 1
- HEWQQGVIJBRBEN-AWEZNQCLSA-N 3-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyridin-4-yl]propan-1-ol Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=CC(CCCO)=CC=1NC1=CN=CC=N1 HEWQQGVIJBRBEN-AWEZNQCLSA-N 0.000 claims 1
- IWCMBJMGYGDOPN-AWEZNQCLSA-N 3-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]benzamide Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)C=2C=C(C=CC=2)C(N)=O)=NC=1NC1=CN=CC=N1 IWCMBJMGYGDOPN-AWEZNQCLSA-N 0.000 claims 1
- GXXMQGAUDBPCAA-HNNXBMFYSA-N 3-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]benzonitrile Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)C=2C=C(C=CC=2)C#N)=NC=1NC1=CN=CC=N1 GXXMQGAUDBPCAA-HNNXBMFYSA-N 0.000 claims 1
- OHPQYQSJJFZXAS-AWEZNQCLSA-N 3-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]pyridine-4-carbonitrile Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)C=2C(=CC=NC=2)C#N)=NC=1NC1=CN=CC=N1 OHPQYQSJJFZXAS-AWEZNQCLSA-N 0.000 claims 1
- CHOMBFHVEVPOAK-ZDUSSCGKSA-N 3-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]pyridine-4-carboxamide Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)C=2C(=CC=NC=2)C(N)=O)=NC=1NC1=CN=CC=N1 CHOMBFHVEVPOAK-ZDUSSCGKSA-N 0.000 claims 1
- MVRAKUCQZAHJDU-AWEZNQCLSA-N 3-cyclopropyl-1-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]azetidin-3-ol Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)N2CC(O)(C2)C2CC2)=NC=1NC1=CN=CC=N1 MVRAKUCQZAHJDU-AWEZNQCLSA-N 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- BJVPCOYTLNNUOJ-KRWDZBQOSA-N 4-(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)-6-n-[(1s)-1-(4-fluorophenyl)ethyl]-2-n-pyrazin-2-ylpyridine-2,6-diamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=CC(N2CCC3(CC2)OCCO3)=CC=1NC1=CN=CC=N1 BJVPCOYTLNNUOJ-KRWDZBQOSA-N 0.000 claims 1
- NEJSRRHHQMTOQA-HNNXBMFYSA-N 4-(1-cyclopropylpyrazol-4-yl)-6-n-[(1s)-1-(4-fluorophenyl)ethyl]-2-n-pyrazin-2-ylpyridine-2,6-diamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=CC(C2=CN(N=C2)C2CC2)=CC=1NC1=CN=CC=N1 NEJSRRHHQMTOQA-HNNXBMFYSA-N 0.000 claims 1
- WKHWJRUZCMHAKP-HNNXBMFYSA-N 4-(1-ethylpyrazol-4-yl)-6-n-[(1s)-1-(4-fluorophenyl)ethyl]-2-n-pyrazin-2-ylpyridine-2,6-diamine Chemical compound C1=NN(CC)C=C1C1=CC(N[C@@H](C)C=2C=CC(F)=CC=2)=NC(NC=2N=CC=NC=2)=C1 WKHWJRUZCMHAKP-HNNXBMFYSA-N 0.000 claims 1
- HHYLSCIMDPCJBW-ZDUSSCGKSA-N 4-(3,3-difluoroazetidin-1-yl)-6-n-[(1s)-1-(4-fluorophenyl)ethyl]-2-n-pyrazin-2-ylpyridine-2,6-diamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=CC(N2CC(F)(F)C2)=CC=1NC1=CN=CC=N1 HHYLSCIMDPCJBW-ZDUSSCGKSA-N 0.000 claims 1
- NJLPODRAMQEGRH-INIZCTEOSA-N 4-(3-cyclopropyl-3-methoxyazetidin-1-yl)-6-n-[(1s)-1-(4-fluorophenyl)ethyl]-2-n-pyrazin-2-ylpyridine-2,6-diamine Chemical compound C1([C@H](C)NC=2C=C(C=C(NC=3N=CC=NC=3)N=2)N2CC(C2)(OC)C2CC2)=CC=C(F)C=C1 NJLPODRAMQEGRH-INIZCTEOSA-N 0.000 claims 1
- OKIXBKADHGTOCD-HNNXBMFYSA-N 4-(4-fluorophenyl)-6-n-[(1s)-1-(4-fluorophenyl)ethyl]-2-n-pyrazin-2-ylpyridine-2,6-diamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=CC(C=2C=CC(F)=CC=2)=CC=1NC1=CN=CC=N1 OKIXBKADHGTOCD-HNNXBMFYSA-N 0.000 claims 1
- NKXITGRFNJGCIU-AWEZNQCLSA-N 4-(cyclopropylmethoxy)-6-n-[(1s)-1-(4-fluorophenyl)ethyl]-2-n-pyrazin-2-ylpyridine-2,6-diamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(NC=1N=CC=NC=1)C=1)=CC=1OCC1CC1 NKXITGRFNJGCIU-AWEZNQCLSA-N 0.000 claims 1
- PNGYBVSPEJTITC-INIZCTEOSA-N 4-[1-(cyclopropylmethyl)pyrazol-4-yl]-6-n-[(1s)-1-(4-fluorophenyl)ethyl]-2-n-pyrazin-2-ylpyridine-2,6-diamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=CC(C2=CN(CC3CC3)N=C2)=CC=1NC1=CN=CC=N1 PNGYBVSPEJTITC-INIZCTEOSA-N 0.000 claims 1
- PLYXTJLZWLXZGS-HNNXBMFYSA-N 4-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyridin-4-yl]benzamide Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=CC(C=2C=CC(=CC=2)C(N)=O)=CC=1NC1=CN=CC=N1 PLYXTJLZWLXZGS-HNNXBMFYSA-N 0.000 claims 1
- CLMSFGKMZIPRSK-HNNXBMFYSA-N 4-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyridin-4-yl]benzenesulfonamide Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=CC(C=2C=CC(=CC=2)S(N)(=O)=O)=CC=1NC1=CN=CC=N1 CLMSFGKMZIPRSK-HNNXBMFYSA-N 0.000 claims 1
- XZNVDGQNALXJKC-ZDUSSCGKSA-N 4-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]-1h-pyridin-2-one Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)C=2C=C(O)N=CC=2)=NC=1NC1=CN=CC=N1 XZNVDGQNALXJKC-ZDUSSCGKSA-N 0.000 claims 1
- QLUWOZLFVNOUFN-ZDUSSCGKSA-N 4-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]piperazin-2-one Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)N2CC(=O)NCC2)=NC=1NC1=CN=CC=N1 QLUWOZLFVNOUFN-ZDUSSCGKSA-N 0.000 claims 1
- WFHBXDDTNRJWAY-LBPRGKRZSA-N 4-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]piperazine-2,6-dione Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)N2CC(=O)NC(=O)C2)=NC=1NC1=CN=CC=N1 WFHBXDDTNRJWAY-LBPRGKRZSA-N 0.000 claims 1
- FXFLZMFTNXGGEH-KNVGNIICSA-N 4-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]piperazine-2-carboxamide Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)N2CC(NCC2)C(N)=O)=NC=1NC1=CN=CC=N1 FXFLZMFTNXGGEH-KNVGNIICSA-N 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- CLYUGKZXMSCRCB-LBPRGKRZSA-N 4-n-(2-aminoethyl)-2-n-[(1s)-1-(4-fluorophenyl)ethyl]-6-n-pyrazin-2-ylpyrimidine-2,4,6-triamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=NC(NCCN)=CC=1NC1=CN=CC=N1 CLYUGKZXMSCRCB-LBPRGKRZSA-N 0.000 claims 1
- KAAFJNHBYBXGGM-AWEZNQCLSA-N 5-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyridin-4-yl]-1h-pyridin-2-one Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=CC(C=2C=NC(O)=CC=2)=CC=1NC1=CN=CC=N1 KAAFJNHBYBXGGM-AWEZNQCLSA-N 0.000 claims 1
- GQOAWOYLRLXORR-ZDUSSCGKSA-N 5-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]-1h-pyridin-2-one Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)C=2C=NC(O)=CC=2)=NC=1NC1=CN=CC=N1 GQOAWOYLRLXORR-ZDUSSCGKSA-N 0.000 claims 1
- FIPSKMCCRCYYTN-AWEZNQCLSA-N 5-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]pyridine-2-carbonitrile Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)C=2C=NC(=CC=2)C#N)=NC=1NC1=CN=CC=N1 FIPSKMCCRCYYTN-AWEZNQCLSA-N 0.000 claims 1
- WGPFECMWOVGPAA-ZDUSSCGKSA-N 5-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]pyridine-2-carboxamide Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)C=2C=NC(=CC=2)C(N)=O)=NC=1NC1=CN=CC=N1 WGPFECMWOVGPAA-ZDUSSCGKSA-N 0.000 claims 1
- RLPPCMIHROZCAU-AWEZNQCLSA-N 5-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]pyridine-3-carbonitrile Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)C=2C=C(C=NC=2)C#N)=NC=1NC1=CN=CC=N1 RLPPCMIHROZCAU-AWEZNQCLSA-N 0.000 claims 1
- GGHMYEGABAHQHB-ZDUSSCGKSA-N 5-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]pyridine-3-carboxamide Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)C=2C=C(C=NC=2)C(N)=O)=NC=1NC1=CN=CC=N1 GGHMYEGABAHQHB-ZDUSSCGKSA-N 0.000 claims 1
- CXGZBMYXOYNZJW-AWEZNQCLSA-N 6-(1,3-benzodioxol-5-yl)-2-n-[(1s)-1-(4-fluorophenyl)ethyl]-4-n-pyrazin-2-ylpyrimidine-2,4-diamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)C=2C=C3OCOC3=CC=2)=NC=1NC1=CN=CC=N1 CXGZBMYXOYNZJW-AWEZNQCLSA-N 0.000 claims 1
- OQPPNIKVERORQC-INIZCTEOSA-N 6-(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)-2-n-[(1s)-1-(4-fluorophenyl)ethyl]-4-n-pyrazin-2-ylpyrimidine-2,4-diamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)N2CCC3(CC2)OCCO3)=NC=1NC1=CN=CC=N1 OQPPNIKVERORQC-INIZCTEOSA-N 0.000 claims 1
- BVFVZIQVEORIRV-LBPRGKRZSA-N 6-(3,3-difluoroazetidin-1-yl)-2-n-[(1s)-1-(4-fluorophenyl)ethyl]-4-n-pyrazin-2-ylpyrimidine-2,4-diamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)N2CC(F)(F)C2)=NC=1NC1=CN=CC=N1 BVFVZIQVEORIRV-LBPRGKRZSA-N 0.000 claims 1
- LMFAZHSBTKMDFF-KNVGNIICSA-N 6-(3-aminopyrrolidin-1-yl)-2-n-[(1s)-1-(4-fluorophenyl)ethyl]-4-n-pyrazin-2-ylpyrimidine-2,4-diamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)N2CC(N)CC2)=NC=1NC1=CN=CC=N1 LMFAZHSBTKMDFF-KNVGNIICSA-N 0.000 claims 1
- SFJSIKXEOQTZGL-LBPRGKRZSA-N 6-(3-fluoroazetidin-1-yl)-2-n-[(1s)-1-(4-fluorophenyl)ethyl]-4-n-pyrazin-2-ylpyrimidine-2,4-diamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)N2CC(F)C2)=NC=1NC1=CN=CC=N1 SFJSIKXEOQTZGL-LBPRGKRZSA-N 0.000 claims 1
- XEZLDVHKHFMGDN-ZDUSSCGKSA-N 6-(azetidin-1-yl)-2-n-[(1s)-1-(4-fluorophenyl)ethyl]-4-n-pyrazin-2-ylpyrimidine-2,4-diamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)N2CCC2)=NC=1NC1=CN=CC=N1 XEZLDVHKHFMGDN-ZDUSSCGKSA-N 0.000 claims 1
- HQUZGIBGCBMCSX-AWEZNQCLSA-N 6-[2-(dimethylamino)ethoxy]-2-n-[(1s)-1-(4-fluorophenyl)ethyl]-4-n-pyrazin-2-ylpyrimidine-2,4-diamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(OCCN(C)C)C=1)=NC=1NC1=CN=CC=N1 HQUZGIBGCBMCSX-AWEZNQCLSA-N 0.000 claims 1
- JWEJYNLMQBOIPE-ZDUSSCGKSA-N 6-[3-(aminomethyl)azetidin-1-yl]-2-n-[(1s)-1-(4-fluorophenyl)ethyl]-4-n-pyrazin-2-ylpyrimidine-2,4-diamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)N2CC(CN)C2)=NC=1NC1=CN=CC=N1 JWEJYNLMQBOIPE-ZDUSSCGKSA-N 0.000 claims 1
- OMTFSXHSRXSFER-AWEZNQCLSA-N 6-[3-(dimethylamino)azetidin-1-yl]-2-n-[(1s)-1-(4-fluorophenyl)ethyl]-4-n-pyrazin-2-ylpyrimidine-2,4-diamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)N2CC(C2)N(C)C)=NC=1NC1=CN=CC=N1 OMTFSXHSRXSFER-AWEZNQCLSA-N 0.000 claims 1
- SHXFEYVXKZQNQB-IBGZPJMESA-N 6-[4-(benzenesulfonyl)piperazin-1-yl]-2-n-[(1s)-1-(4-fluorophenyl)ethyl]-4-n-pyrazin-2-ylpyrimidine-2,4-diamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)N2CCN(CC2)S(=O)(=O)C=2C=CC=CC=2)=NC=1NC1=CN=CC=N1 SHXFEYVXKZQNQB-IBGZPJMESA-N 0.000 claims 1
- CDQNUSZDXWJYKJ-JTQLQIEISA-N 6-chloro-2-n-[(1s)-1-(4-fluorophenyl)ethyl]-4-n-pyrazin-2-ylpyrimidine-2,4-diamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=NC(Cl)=CC=1NC1=CN=CC=N1 CDQNUSZDXWJYKJ-JTQLQIEISA-N 0.000 claims 1
- VNHROOBCPXWUIU-AWEZNQCLSA-N 6-n-[(1s)-1-(4-fluorophenyl)ethyl]-2-n,4-n-di(pyrazin-2-yl)pyridine-2,4,6-triamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(NC=1N=CC=NC=1)C=1)=CC=1NC1=CN=CC=N1 VNHROOBCPXWUIU-AWEZNQCLSA-N 0.000 claims 1
- HNZUJPIUOUQLMQ-HNNXBMFYSA-N 6-n-[(1s)-1-(4-fluorophenyl)ethyl]-2-n-(5-methylpyrazin-2-yl)-4-(1-methylpyrazol-4-yl)pyridine-2,6-diamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=CC(C2=CN(C)N=C2)=CC=1NC1=CN=C(C)C=N1 HNZUJPIUOUQLMQ-HNNXBMFYSA-N 0.000 claims 1
- WZCZKMGJVYCMNO-ZDUSSCGKSA-N 6-n-[(1s)-1-(4-fluorophenyl)ethyl]-2-n-pyrazin-2-yl-4-(1h-pyrazol-4-yl)pyridine-2,6-diamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=CC(C2=CNN=C2)=CC=1NC1=CN=CC=N1 WZCZKMGJVYCMNO-ZDUSSCGKSA-N 0.000 claims 1
- LLBVAJNMSCDXSL-ZDUSSCGKSA-N 6-n-[(1s)-1-(4-fluorophenyl)ethyl]-2-n-pyrazin-2-yl-4-(1h-pyrazol-5-yl)pyridine-2,6-diamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=CC(C2=NNC=C2)=CC=1NC1=CN=CC=N1 LLBVAJNMSCDXSL-ZDUSSCGKSA-N 0.000 claims 1
- ZIZBYOWLOJXAHG-HNNXBMFYSA-N 6-n-[(1s)-1-(4-fluorophenyl)ethyl]-2-n-pyrazin-2-yl-4-n-pyridin-2-ylpyridine-2,4,6-triamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(NC=1N=CC=NC=1)C=1)=CC=1NC1=CC=CC=N1 ZIZBYOWLOJXAHG-HNNXBMFYSA-N 0.000 claims 1
- QELQSSHBTVYYEH-AWEZNQCLSA-N 6-n-[(1s)-1-(4-fluorophenyl)ethyl]-2-n-pyrazin-2-yl-4-n-pyrimidin-2-ylpyridine-2,4,6-triamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(NC=1N=CC=NC=1)C=1)=CC=1NC1=NC=CC=N1 QELQSSHBTVYYEH-AWEZNQCLSA-N 0.000 claims 1
- LRUIQLSPTFZRGH-HNNXBMFYSA-N 6-n-[(1s)-1-(4-fluorophenyl)ethyl]-2-n-pyrazin-2-yl-4-thiomorpholin-4-ylpyridine-2,6-diamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=CC(N2CCSCC2)=CC=1NC1=CN=CC=N1 LRUIQLSPTFZRGH-HNNXBMFYSA-N 0.000 claims 1
- CIZZUINNRPTWCB-LBPRGKRZSA-N 6-n-[(1s)-1-(4-fluorophenyl)ethyl]-2-n-pyrazin-2-ylpyridine-2,6-diamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=CC=CC=1NC1=CN=CC=N1 CIZZUINNRPTWCB-LBPRGKRZSA-N 0.000 claims 1
- VSBMAVCPBZGSKV-LBPRGKRZSA-N 6-n-[(1s)-1-(4-fluorophenyl)ethyl]-4-(1,2,4-oxadiazol-3-yl)-2-n-pyrazin-2-ylpyridine-2,6-diamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=CC(C2=NOC=N2)=CC=1NC1=CN=CC=N1 VSBMAVCPBZGSKV-LBPRGKRZSA-N 0.000 claims 1
- XYXFEAIQCJYWPF-ZDUSSCGKSA-N 6-n-[(1s)-1-(4-fluorophenyl)ethyl]-4-(1,3-oxazol-5-yl)-2-n-pyrazin-2-ylpyridine-2,6-diamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=CC(C=2OC=NC=2)=CC=1NC1=CN=CC=N1 XYXFEAIQCJYWPF-ZDUSSCGKSA-N 0.000 claims 1
- UOZHUDUAQTXPFV-INIZCTEOSA-N 6-n-[(1s)-1-(4-fluorophenyl)ethyl]-4-(1-methylsulfonylpiperidin-4-yl)-2-n-pyrazin-2-ylpyridine-2,6-diamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=CC(C2CCN(CC2)S(C)(=O)=O)=CC=1NC1=CN=CC=N1 UOZHUDUAQTXPFV-INIZCTEOSA-N 0.000 claims 1
- JOCOVBYEJCRJKI-INIZCTEOSA-N 6-n-[(1s)-1-(4-fluorophenyl)ethyl]-4-(1-propan-2-ylpyrazol-4-yl)-2-n-pyrazin-2-ylpyridine-2,6-diamine Chemical compound C1=NN(C(C)C)C=C1C1=CC(N[C@@H](C)C=2C=CC(F)=CC=2)=NC(NC=2N=CC=NC=2)=C1 JOCOVBYEJCRJKI-INIZCTEOSA-N 0.000 claims 1
- CZOXSLWHHSZYKA-AWEZNQCLSA-N 6-n-[(1s)-1-(4-fluorophenyl)ethyl]-4-(2-methoxyethoxy)-2-n-pyrazin-2-ylpyridine-2,6-diamine Chemical compound C1([C@H](C)NC=2C=C(C=C(NC=3N=CC=NC=3)N=2)OCCOC)=CC=C(F)C=C1 CZOXSLWHHSZYKA-AWEZNQCLSA-N 0.000 claims 1
- LBZOAGGAZJBFGS-AWEZNQCLSA-N 6-n-[(1s)-1-(4-fluorophenyl)ethyl]-4-(2-methylpyrazol-3-yl)-2-n-pyrazin-2-ylpyridine-2,6-diamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=CC(C=2N(N=CC=2)C)=CC=1NC1=CN=CC=N1 LBZOAGGAZJBFGS-AWEZNQCLSA-N 0.000 claims 1
- GKZCRZSMXXQROX-HNNXBMFYSA-N 6-n-[(1s)-1-(4-fluorophenyl)ethyl]-4-(3-methoxy-3-methylazetidin-1-yl)-2-n-pyrazin-2-ylpyridine-2,6-diamine Chemical compound C1C(OC)(C)CN1C1=CC(N[C@@H](C)C=2C=CC(F)=CC=2)=NC(NC=2N=CC=NC=2)=C1 GKZCRZSMXXQROX-HNNXBMFYSA-N 0.000 claims 1
- JJUSXEUWTNRIGD-KRWDZBQOSA-N 6-n-[(1s)-1-(4-fluorophenyl)ethyl]-4-(3-methoxy-3-propan-2-ylazetidin-1-yl)-2-n-pyrazin-2-ylpyridine-2,6-diamine Chemical compound C1C(OC)(C(C)C)CN1C1=CC(N[C@@H](C)C=2C=CC(F)=CC=2)=NC(NC=2N=CC=NC=2)=C1 JJUSXEUWTNRIGD-KRWDZBQOSA-N 0.000 claims 1
- SUSACRLCVZFCMJ-KRWDZBQOSA-N 6-n-[(1s)-1-(4-fluorophenyl)ethyl]-4-(3-morpholin-4-ylazetidin-1-yl)-2-n-pyrazin-2-ylpyridine-2,6-diamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=CC(N2CC(C2)N2CCOCC2)=CC=1NC1=CN=CC=N1 SUSACRLCVZFCMJ-KRWDZBQOSA-N 0.000 claims 1
- YYYDOUSOWVHETO-INIZCTEOSA-N 6-n-[(1s)-1-(4-fluorophenyl)ethyl]-4-(4-methoxyphenyl)-2-n-pyrazin-2-ylpyridine-2,6-diamine Chemical compound C1=CC(OC)=CC=C1C1=CC(N[C@@H](C)C=2C=CC(F)=CC=2)=NC(NC=2N=CC=NC=2)=C1 YYYDOUSOWVHETO-INIZCTEOSA-N 0.000 claims 1
- XCKKLLRKBLENNE-HNNXBMFYSA-N 6-n-[(1s)-1-(4-fluorophenyl)ethyl]-4-(4-methylimidazol-1-yl)-2-n-pyrazin-2-ylpyridine-2,6-diamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=CC(N2C=C(C)N=C2)=CC=1NC1=CN=CC=N1 XCKKLLRKBLENNE-HNNXBMFYSA-N 0.000 claims 1
- MTYLWQMZISIJFH-INIZCTEOSA-N 6-n-[(1s)-1-(4-fluorophenyl)ethyl]-4-(4-methylsulfonylphenyl)-2-n-pyrazin-2-ylpyridine-2,6-diamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=CC(C=2C=CC(=CC=2)S(C)(=O)=O)=CC=1NC1=CN=CC=N1 MTYLWQMZISIJFH-INIZCTEOSA-N 0.000 claims 1
- WSLZPLFKPCYYQN-INIZCTEOSA-N 6-n-[(1s)-1-(4-fluorophenyl)ethyl]-4-(4-methylsulfonylpiperazin-1-yl)-2-n-pyrazin-2-ylpyridine-2,6-diamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=CC(N2CCN(CC2)S(C)(=O)=O)=CC=1NC1=CN=CC=N1 WSLZPLFKPCYYQN-INIZCTEOSA-N 0.000 claims 1
- CVWAVDIKDPEYBS-AWEZNQCLSA-N 6-n-[(1s)-1-(4-fluorophenyl)ethyl]-4-(furan-3-yl)-2-n-pyrazin-2-ylpyridine-2,6-diamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=CC(C2=COC=C2)=CC=1NC1=CN=CC=N1 CVWAVDIKDPEYBS-AWEZNQCLSA-N 0.000 claims 1
- JNGHNSGLPVLCQI-ZDUSSCGKSA-N 6-n-[(1s)-1-(4-fluorophenyl)ethyl]-4-(methoxymethyl)-2-n-pyrazin-2-ylpyridine-2,6-diamine Chemical compound C1([C@H](C)NC=2C=C(C=C(NC=3N=CC=NC=3)N=2)COC)=CC=C(F)C=C1 JNGHNSGLPVLCQI-ZDUSSCGKSA-N 0.000 claims 1
- JBSRGIYWFJYEMK-HNNXBMFYSA-N 6-n-[(1s)-1-(4-fluorophenyl)ethyl]-4-(oxan-4-yloxy)-2-n-pyrazin-2-ylpyridine-2,6-diamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(NC=1N=CC=NC=1)C=1)=CC=1OC1CCOCC1 JBSRGIYWFJYEMK-HNNXBMFYSA-N 0.000 claims 1
- VDBYKHBLFCWQFR-INIZCTEOSA-N 6-n-[(1s)-1-(4-fluorophenyl)ethyl]-4-[1-(2-methoxyethyl)pyrazol-4-yl]-2-n-pyrazin-2-ylpyridine-2,6-diamine Chemical compound C1=NN(CCOC)C=C1C1=CC(N[C@@H](C)C=2C=CC(F)=CC=2)=NC(NC=2N=CC=NC=2)=C1 VDBYKHBLFCWQFR-INIZCTEOSA-N 0.000 claims 1
- IHFCGOIVTUYEPH-HNNXBMFYSA-N 6-n-[(1s)-1-(4-fluorophenyl)ethyl]-4-[1-(methoxymethyl)pyrazol-4-yl]-2-n-pyrazin-2-ylpyridine-2,6-diamine Chemical compound C1=NN(COC)C=C1C1=CC(N[C@@H](C)C=2C=CC(F)=CC=2)=NC(NC=2N=CC=NC=2)=C1 IHFCGOIVTUYEPH-HNNXBMFYSA-N 0.000 claims 1
- FMISFRKBWPORIT-LBPRGKRZSA-N 6-n-[(1s)-1-(4-fluorophenyl)ethyl]-4-methoxy-2-n-pyrazin-2-ylpyridine-2,6-diamine Chemical compound C1([C@H](C)NC=2C=C(C=C(NC=3N=CC=NC=3)N=2)OC)=CC=C(F)C=C1 FMISFRKBWPORIT-LBPRGKRZSA-N 0.000 claims 1
- GGGNYJCJKGTJLK-ZDUSSCGKSA-N 6-n-[(1s)-1-(4-fluorophenyl)ethyl]-4-methyl-2-n-pyrazin-2-ylpyridine-2,6-diamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=CC(C)=CC=1NC1=CN=CC=N1 GGGNYJCJKGTJLK-ZDUSSCGKSA-N 0.000 claims 1
- WEKBZCBPCNITEI-HNNXBMFYSA-N 6-n-[(1s)-1-(4-fluorophenyl)ethyl]-4-morpholin-4-yl-2-n-pyrazin-2-ylpyridine-2,6-diamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=CC(N2CCOCC2)=CC=1NC1=CN=CC=N1 WEKBZCBPCNITEI-HNNXBMFYSA-N 0.000 claims 1
- ZYUDXRXJTDCNNC-HNNXBMFYSA-N 6-n-[(1s)-1-(4-fluorophenyl)ethyl]-6-n-methyl-4-(1-methylpyrazol-4-yl)-2-n-pyrazin-2-ylpyridine-2,6-diamine Chemical compound CN([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=CC(C2=CN(C)N=C2)=CC=1NC1=CN=CC=N1 ZYUDXRXJTDCNNC-HNNXBMFYSA-N 0.000 claims 1
- BLBHXJPLXJSUGS-AWEZNQCLSA-N 6-n-[2-(dimethylamino)ethyl]-2-n-[(1s)-1-(4-fluorophenyl)ethyl]-4-n-pyrazin-2-ylpyrimidine-2,4,6-triamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=NC(NCCN(C)C)=CC=1NC1=CN=CC=N1 BLBHXJPLXJSUGS-AWEZNQCLSA-N 0.000 claims 1
- KDPIQLKDURLHRR-HNNXBMFYSA-N 8-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]-8-azaspiro[4.5]decane-2,3,4-trione Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)N2CCC3(C(C(=O)C(=O)C3)=O)CC2)=NC=1NC1=CN=CC=N1 KDPIQLKDURLHRR-HNNXBMFYSA-N 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 206010002329 Aneurysm Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 208000032027 Essential Thrombocythemia Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010046996 Varicose vein Diseases 0.000 claims 1
- QHYLJILWSSVSLB-INIZCTEOSA-N [1-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]azetidin-3-yl]-morpholin-4-ylmethanone Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)N2CC(C2)C(=O)N2CCOCC2)=NC=1NC1=CN=CC=N1 QHYLJILWSSVSLB-INIZCTEOSA-N 0.000 claims 1
- YDXOXXMDJLZCQL-KRWDZBQOSA-N [1-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]azetidin-3-yl]-piperidin-1-ylmethanone Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)N2CC(C2)C(=O)N2CCCCC2)=NC=1NC1=CN=CC=N1 YDXOXXMDJLZCQL-KRWDZBQOSA-N 0.000 claims 1
- IXTZNQOFEHNJEY-INIZCTEOSA-N [1-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]azetidin-3-yl]-pyrrolidin-1-ylmethanone Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)N2CC(C2)C(=O)N2CCCC2)=NC=1NC1=CN=CC=N1 IXTZNQOFEHNJEY-INIZCTEOSA-N 0.000 claims 1
- VTVFELPAJPZRJX-ZDUSSCGKSA-N [1-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]azetidin-3-yl]methanol Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)N2CC(CO)C2)=NC=1NC1=CN=CC=N1 VTVFELPAJPZRJX-ZDUSSCGKSA-N 0.000 claims 1
- SQFHLJBBDSLIRF-LBPRGKRZSA-N [1-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]azetidin-3-yl]urea Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)N2CC(C2)NC(N)=O)=NC=1NC1=CN=CC=N1 SQFHLJBBDSLIRF-LBPRGKRZSA-N 0.000 claims 1
- DPCWNUDCMLXMRM-INIZCTEOSA-N [2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyridin-4-yl]-(4-methylpiperazin-1-yl)methanone Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=CC(C(=O)N2CCN(C)CC2)=CC=1NC1=CN=CC=N1 DPCWNUDCMLXMRM-INIZCTEOSA-N 0.000 claims 1
- NVSFBNGYKHTPPY-INIZCTEOSA-N [2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyridin-4-yl]-(4-methylsulfonylpiperazin-1-yl)methanone Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=CC(C(=O)N2CCN(CC2)S(C)(=O)=O)=CC=1NC1=CN=CC=N1 NVSFBNGYKHTPPY-INIZCTEOSA-N 0.000 claims 1
- GPTOOPNAMNMIHS-HNNXBMFYSA-N [2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyridin-4-yl]-morpholin-4-ylmethanone Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=CC(C(=O)N2CCOCC2)=CC=1NC1=CN=CC=N1 GPTOOPNAMNMIHS-HNNXBMFYSA-N 0.000 claims 1
- BCWJLKGUULEOKY-HNNXBMFYSA-N [2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyridin-4-yl]-pyrrolidin-1-ylmethanone Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=CC(C(=O)N2CCCC2)=CC=1NC1=CN=CC=N1 BCWJLKGUULEOKY-HNNXBMFYSA-N 0.000 claims 1
- BFFVUOOCOOTDMA-LBPRGKRZSA-N [2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyridin-4-yl]methanol Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=CC(CO)=CC=1NC1=CN=CC=N1 BFFVUOOCOOTDMA-LBPRGKRZSA-N 0.000 claims 1
- QCXQIEBFUBUQPC-NSHDSACASA-N [2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyridin-4-yl]urea Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=CC(NC(N)=O)=CC=1NC1=CN=CC=N1 QCXQIEBFUBUQPC-NSHDSACASA-N 0.000 claims 1
- 208000017733 acquired polycythemia vera Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 1
- SLXAKRCXCJOGKK-INIZCTEOSA-N ethyl 1-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1C1=CC(NC=2N=CC=NC=2)=NC(N[C@@H](C)C=2C=CC(F)=CC=2)=N1 SLXAKRCXCJOGKK-INIZCTEOSA-N 0.000 claims 1
- 125000001207 fluorophenyl group Chemical group 0.000 claims 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N gamma-butyrolactam Natural products O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims 1
- UQTPDWDAYHAZNT-AWEZNQCLSA-N ilginatinib Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=CC(C2=CN(C)N=C2)=CC=1NC1=CN=CC=N1 UQTPDWDAYHAZNT-AWEZNQCLSA-N 0.000 claims 1
- VFQXVTODMYMSMJ-UHFFFAOYSA-N isonicotinamide Chemical compound NC(=O)C1=CC=NC=C1 VFQXVTODMYMSMJ-UHFFFAOYSA-N 0.000 claims 1
- OZRMOBHKZKJXTK-LBPRGKRZSA-N methyl 2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyridine-3-carboxylate Chemical compound N1=C(N[C@@H](C)C=2C=CC(F)=CC=2)C(C(=O)OC)=CC=C1NC1=CN=CC=N1 OZRMOBHKZKJXTK-LBPRGKRZSA-N 0.000 claims 1
- NWYHINIPXDUMBD-LBPRGKRZSA-N methyl 2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyridine-4-carboxylate Chemical compound C1([C@H](C)NC=2C=C(C=C(NC=3N=CC=NC=3)N=2)C(=O)OC)=CC=C(F)C=C1 NWYHINIPXDUMBD-LBPRGKRZSA-N 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- UUOOGMYMGDYUBZ-HNNXBMFYSA-N n-(2-ethoxyethyl)-2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyridine-4-carboxamide Chemical compound C1([C@H](C)NC=2C=C(C=C(NC=3N=CC=NC=3)N=2)C(=O)NCCOCC)=CC=C(F)C=C1 UUOOGMYMGDYUBZ-HNNXBMFYSA-N 0.000 claims 1
- GYELJUSFRTXOMH-HNNXBMFYSA-N n-(cyclopropylmethyl)-1-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]azetidine-3-carboxamide Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)N2CC(C2)C(=O)NCC2CC2)=NC=1NC1=CN=CC=N1 GYELJUSFRTXOMH-HNNXBMFYSA-N 0.000 claims 1
- OXLUYFKXOYVPGP-AWEZNQCLSA-N n-(cyclopropylmethyl)-2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyridine-3-carboxamide Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(C(=CC=1)C(=O)NCC2CC2)=NC=1NC1=CN=CC=N1 OXLUYFKXOYVPGP-AWEZNQCLSA-N 0.000 claims 1
- MFTBCZLQMZZGCS-AWEZNQCLSA-N n-(cyclopropylmethyl)-2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyridine-4-carboxamide Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=CC(C(=O)NCC2CC2)=CC=1NC1=CN=CC=N1 MFTBCZLQMZZGCS-AWEZNQCLSA-N 0.000 claims 1
- BUCZCHGSUGHQBB-KBXCAEBGSA-N n-[(3r)-1-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]pyrrolidin-3-yl]acetamide Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)N2C[C@@H](CC2)NC(C)=O)=NC=1NC1=CN=CC=N1 BUCZCHGSUGHQBB-KBXCAEBGSA-N 0.000 claims 1
- BUCZCHGSUGHQBB-KSSFIOAISA-N n-[(3s)-1-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]pyrrolidin-3-yl]acetamide Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)N2C[C@H](CC2)NC(C)=O)=NC=1NC1=CN=CC=N1 BUCZCHGSUGHQBB-KSSFIOAISA-N 0.000 claims 1
- HJGHIUQFFXFJNQ-ZDUSSCGKSA-N n-[1-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]azetidin-3-yl]acetamide Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)N2CC(C2)NC(C)=O)=NC=1NC1=CN=CC=N1 HJGHIUQFFXFJNQ-ZDUSSCGKSA-N 0.000 claims 1
- MJPOYJSTACHJRV-AWEZNQCLSA-N n-[1-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]azetidin-3-yl]ethanesulfonamide Chemical compound C1C(NS(=O)(=O)CC)CN1C1=CC(NC=2N=CC=NC=2)=NC(N[C@@H](C)C=2C=CC(F)=CC=2)=N1 MJPOYJSTACHJRV-AWEZNQCLSA-N 0.000 claims 1
- QTJDIIOCEFSAAS-ZDUSSCGKSA-N n-[1-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]azetidin-3-yl]methanesulfonamide Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)N2CC(C2)NS(C)(=O)=O)=NC=1NC1=CN=CC=N1 QTJDIIOCEFSAAS-ZDUSSCGKSA-N 0.000 claims 1
- QKYKPHRBCZQSLC-MBIQTGHCSA-N n-[1-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]pyrrolidin-3-yl]methanesulfonamide Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)N2CC(CC2)NS(C)(=O)=O)=NC=1NC1=CN=CC=N1 QKYKPHRBCZQSLC-MBIQTGHCSA-N 0.000 claims 1
- BOQNVCXRURWLRN-LBPRGKRZSA-N n-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyridin-4-yl]acetamide Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=CC(NC(C)=O)=CC=1NC1=CN=CC=N1 BOQNVCXRURWLRN-LBPRGKRZSA-N 0.000 claims 1
- LKTUVGZTJQKSFU-LBPRGKRZSA-N n-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyridin-4-yl]methanesulfonamide Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=CC(NS(C)(=O)=O)=CC=1NC1=CN=CC=N1 LKTUVGZTJQKSFU-LBPRGKRZSA-N 0.000 claims 1
- KPDANEDSHMNEMT-ZDUSSCGKSA-N n-[2-[[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]amino]ethyl]acetamide Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=NC(NCCNC(C)=O)=CC=1NC1=CN=CC=N1 KPDANEDSHMNEMT-ZDUSSCGKSA-N 0.000 claims 1
- JXNUUEYPNMOAGE-ZDUSSCGKSA-N n-[2-[[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]amino]ethyl]methanesulfonamide Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=NC(NCCNS(C)(=O)=O)=CC=1NC1=CN=CC=N1 JXNUUEYPNMOAGE-ZDUSSCGKSA-N 0.000 claims 1
- NLOYPWJDDFXNDV-AWEZNQCLSA-N n-[[1-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]azetidin-3-yl]methyl]acetamide Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)N2CC(CNC(C)=O)C2)=NC=1NC1=CN=CC=N1 NLOYPWJDDFXNDV-AWEZNQCLSA-N 0.000 claims 1
- OHDNTNCQYISUIL-HNNXBMFYSA-N n-[[1-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]azetidin-3-yl]methyl]ethanesulfonamide Chemical compound C1C(CNS(=O)(=O)CC)CN1C1=CC(NC=2N=CC=NC=2)=NC(N[C@@H](C)C=2C=CC(F)=CC=2)=N1 OHDNTNCQYISUIL-HNNXBMFYSA-N 0.000 claims 1
- WRJCQTGURCRZIA-KRWDZBQOSA-N n-benzyl-2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyridine-4-carboxamide Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=CC(C(=O)NCC=2C=CC=CC=2)=CC=1NC1=CN=CC=N1 WRJCQTGURCRZIA-KRWDZBQOSA-N 0.000 claims 1
- FTGZAMAUHQUBIV-HNNXBMFYSA-N n-butyl-2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyridine-4-carboxamide Chemical compound C1([C@H](C)NC=2C=C(C=C(NC=3N=CC=NC=3)N=2)C(=O)NCCCC)=CC=C(F)C=C1 FTGZAMAUHQUBIV-HNNXBMFYSA-N 0.000 claims 1
- GVCUDLQQMFEDGJ-AWEZNQCLSA-N n-cyclobutyl-2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyridine-4-carboxamide Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=CC(C(=O)NC2CCC2)=CC=1NC1=CN=CC=N1 GVCUDLQQMFEDGJ-AWEZNQCLSA-N 0.000 claims 1
- YHEYDDJIWXPABQ-ZDUSSCGKSA-N n-cyclopropyl-2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyridine-4-carboxamide Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=CC(C(=O)NC2CC2)=CC=1NC1=CN=CC=N1 YHEYDDJIWXPABQ-ZDUSSCGKSA-N 0.000 claims 1
- CTYKCFBUCIEOED-ZDUSSCGKSA-N n-ethyl-2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyridine-4-carboxamide Chemical compound C1([C@H](C)NC=2C=C(C=C(NC=3N=CC=NC=3)N=2)C(=O)NCC)=CC=C(F)C=C1 CTYKCFBUCIEOED-ZDUSSCGKSA-N 0.000 claims 1
- OFDATBHMJAYVMG-AWEZNQCLSA-N n-tert-butyl-2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyridine-4-carboxamide Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=CC(C(=O)NC(C)(C)C)=CC=1NC1=CN=CC=N1 OFDATBHMJAYVMG-AWEZNQCLSA-N 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 claims 1
- 208000037244 polycythemia vera Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000003476 primary myelofibrosis Diseases 0.000 claims 1
- 229940080818 propionamide Drugs 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- YITSARZZGZOGNX-INIZCTEOSA-N tert-butyl n-[[1-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl]azetidin-3-yl]methyl]carbamate Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=C(C=1)N2CC(CNC(=O)OC(C)(C)C)C2)=NC=1NC1=CN=CC=N1 YITSARZZGZOGNX-INIZCTEOSA-N 0.000 claims 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/145—Maleic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Claims (14)
1. Spoj kojeg prikazuje sljedeća opća formula [1], ili njegova farmaceutski prihvatljiva sol, naznačen time što je spoj definiran u sljedećim stavcima (I) ili (II):
[image]
(I):
X predstavlja CH ili N;
R1 predstavlja halogen;
R2 predstavlja:
(1) H,
(2) halogen,
(3) cijano,
(4) skupinu koju prikazuje sljedeća opća formula [2]:
[image]
(gdje * ukazuje na položaj za vezanje; a RC, RD i RE su isti ili različiti i svaki od njih predstavlja (a) H, ili (b) alkil, izborno supstituiran s hidroksi ili alkoksi, ili se alternativno dva od RC, RD i RE uzima zajedno sa susjednim C kako bi predstavljali zasićenu heterocikličku skupinu koja sadrži N, a drugi je H, gdje je zasićena heterociklička skupina izborno supstituirana s alkilsulfonilom),
(5) skupinu koju prikazuje sljedeća opća formula [3]:
[image]
(gdje * ima isto značenje kao što je opisano gore; a RF i RG su isti ili različiti i svaki od njih predstavlja (a) H, (b) alkil, izborno supstituiran s jednom ili dvije skupine, koje se bira iz skupine koju čine hidroksi, amino, dialkilamino, zasićena prstenasta amino skupina, alkilkarbonilamino, alkilsulfonilamino, aril, heteroaril izborno supstituiran s alkilom, tetrahidrofuranil i karbamoil, (c) alkilkarbonil, (d) alkilsulfonil, (e) karbamoil ili (f) heteroaril, izborno supstituiran s alkilom, ili se alternativno RF i RG uzima zajedno sa susjednim N kako bi predstavljali zasićenu prstenastu amino skupinu, koja može biti izborno supstituirana s jednom ili dvije skupine, koje se bira iz skupine koju čine (a) halogen, (b) cijano, (c) hidroksi, (d) alkil, izborno supstituiran s jednom ili dvije skupine, koje se bira iz skupine koju čine hidroksi, alkoksi, amino, alkoksikarbonilamino, alkilsulfonilamino i alkilkarbonilamino, (e) cikloalkil, (f) haloalkil, (g) alkoksi, (h) okso, (i) skupina koju prikazuje sljedeća opća formula [4]:
[image]
(gdje * ima isto značenje kao što je opisano gore; a RH predstavlja alkil ili aril), (j) skupina koju prikazuje sljedeća opća formula [5]:
[image]
(gdje * ima isto značenje kao što je opisano gore; a RI i RJ su isti ili različiti i svaki od njih predstavlja H, alkil, karbamoil, alkilkarbonil ili alkilsulfonil), (k) skupina koju prikazuje sljedeća opća formula [6]:
[image]
(gdje * ima isto značenje kao što je opisano gore; a RK predstavlja alkil, hidroksi, amino, alkilamino, dialkilamino, cikloalkilamino, (cikloalkil)alkilamino, (hidroksialkil)amino, (alkoksialkil)amino, alkoksi, alkilsulfonilamino ili zasićenu prstenastu amino skupinu) i (l) zasićena prstenasta amino skupina, izborno supstituirana s hidroksilom; gdje zasićena prstenasta amino skupina, koju se tvori kombiniranjem RF i RG sa susjednim N, može tvoriti spiro-vezu sa skupinom koju prikazuje sljedeća opća formula [7A] ili [7B]:
[image]
(gdje * ima isto značenje kao što je opisano gore)),
(6) skupinu koju prikazuje sljedeća opća formula [8]:
[image]
(gdje * ima isto značenje kao što je opisano gore; a RL predstavlja (a) alkil, (b) hidroksi, (c) alkoksi, (d) zasićenu prstenastu amino skupinu, izborno supstituiranu s alkilom ili alkilsulfonilom, ili (e) amino, izborno supstituiran s jednom ili dvije skupine, koje se bira iz skupine koju čine alkil, cikloalkil, (cikloalkil)alkil, aralkil, haloalkil, dialkilaminoalkil, alkoksialkil i hidroksialkil),
(7) skupinu koju prikazuje sljedeća opća formula [9]:
[image]
(gdje * ima isto značenje kao što je opisano gore; a RM, RN i RO su isti ili različiti i svaki od njih predstavlja H, halogen, cijano, alkoksi, karbamoil, sulfamoil, monoalkilaminosulfonil ili alkilsulfonil, ili se alternativno dva od RM, RN i RO uzima zajedno kako bi predstavljali metilendioksi),
(8) -ORP (RP predstavlja alkil, izborno supstituiran sa skupinom koju se bira iz skupine koju čine hidroksi, dialkilamino, alkoksi, tetrahidrofuranil i cikloalkil, ili izborno zasićenu prstenastu skupinu koja sadrži O, izborno supstituiranu s hidroksi), ili
(9) heteroaril, izborno supstituiran s jednom ili dvije skupine, koje se bira iz skupine koju čine cijano, halogen, hidroksi, alkoksi, alkilkarbonil, karbamoil, alkil, cikloalkil, (cikloalkil)alkil, aralkil, hidroksikarbonil i alkoksialkil;
R3 predstavlja H ili hidroksi;
R4 predstavlja H ili alkil; i
R5 predstavlja H ili alkil;
(II):
X predstavlja -CRA;
RA predstavlja skupinu koju prikazuje sljedeća opća formula [10]:
[image]
(gdje * ima isto značenje kao što je opisano gore; a RB predstavlja (a) amino, izborno supstituiran s jednom ili dvije skupine, koje se bira iz skupine koju čine alkil, cikloalkil, (cikloalkil)alkil i alkoksialkil, (b) alkoksi, (c) hidroksi ili (d) zasićenu prstenastu aminu skupinu);
R1 predstavlja halogen;
R2 predstavlja H;
R3 predstavlja H ili hidroksi;
R4 predstavlja H ili alkil; i
R5 predstavlja H ili alkil.
2. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s patentnim zahtjevom 1, naznačen time što je spoj kojeg prikazuje opća formula [1] definiran u sljedećim stavcima [i] ili [ii]:
[i]:
X je CH ili N; i
R2 je:
(1) skupina koju prikazuje sljedeća opća formula [11]:
[image]
(gdje * ukazuje na položaj za vezanje; a RF1 i RG1 su isti ili različiti i svaki od njih predstavlja (a) H, (b) alkil, izborno supstituiran s jednom ili dvije skupine, koje se bira iz skupine koju čine hidroksi, amino, dialkilamino, zasićena prstenasta amino skupina, alkilkarbonilamino, alkilsulfonilamino, aril, heteroaril izborno supstituiran s alkilom, tetrahidrofuranil i karbamoil, (c) alkilkarbonil, (d) alkilsulfonil, (e) karbamoil ili (f) heteroaril, izborno supstituiran s alkilom, ili se alternativno, RF i RG uzima zajedno sa susjednim N kako bi predstavljali zasićenu prstenastu amino skupinu, koja može biti izborno supstituirana s jednom ili dvije skupine, koje se bira iz skupine koju čine (a) halogen, (b) cijano, (c) hidroksi, (d) alkil, izborno supstituiran s jednom ili dvije skupine, koje se bira iz skupine koju čine hidroksi, alkoksi, amino, alkoksikarbonilamino, alkilsulfonilamino i alkilkarbonilamino, (e) cikloalkil, (f) haloalkil, (g) alkoksi, (h) okso, (i) skupina koju prikazuje sljedeća opća formula [4]:
[image]
(gdje * ima isto značenje kao što je opisano gore; a RH predstavlja alkil ili aril), (j) skupina koju prikazuje sljedeća opća formula [5]:
[image]
(gdje * ima isto značenje kao što je opisano gore; a RI i RJ su isti ili različiti i svaki od njih predstavlja H, alkil, karbamoil, alkilkarbonil ili alkilsulfonil), (k) skupina koju prikazuje sljedeća opća formula [6]:
[image]
(gdje * ima isto značenje kao što je opisano gore; a RK predstavlja alkil, hidroksi, amino, alkilamino, dialkilamino, cikloalkilamino, (cikloalkil)alkilamino, (hidroksialkil)amino, (alkoksialkil)amino, alkoksi, alkilsulfonilamino ili zasićenu prstenastu amino skupinu) i (l) zasićena prstenasta amino skupina, izborno supstituirana s hidroksilom,
(2) skupina koju prikazuje sljedeća opća formula [8]:
[image]
(gdje * ima isto značenje kao što je opisano gore; a RL predstavlja (a) alkil, (b) hidroksi, (c) alkoksi, (d) zasićenu prstenastu amino skupinu, izborno supstituiranu s alkilom ili alkilsulfonilom, ili (e) amino, izborno supstituiran s jednom ili dvije skupine, koje se bira iz skupine koju čine alkil, cikloalkil, (cikloalkil)alkil, aralkil, haloalkil, dialkilaminoalkil, alkoksialkil i hidroksialkil),
(3) skupina koju prikazuje sljedeća opća formula [9]:
[image]
(gdje * ima isto značenje kao što je opisano gore; a RM, RN i RO su isti ili različiti i svaki od njih predstavlja H, halogen, cijano, alkoksi, karbamoil, sulfamoil, monoalkilaminosulfonil ili alkilsulfonil, ili se alternativno dva od RM, RN i RO uzima zajedno kako bi predstavljali metilendioksi),
(4) -ORP1 (gdje RP1 predstavlja alkil, izborno supstituiran sa skupinom koju se bira iz skupine koju čine hidroksi, dialkilamino, alkoksi, tetrahidrofuranil i cikloalkil), ili
(5) heteroaril, izborno supstituiran s jednom ili dvije skupine, koje se bira iz skupine koju čine cijano, halogen, hidroksi, alkoksi, alkilkarbonil, karbamoil, alkil, cikloalkil, (cikloalkil)alkil, aralkil, hidroksikarbonil i alkoksialkil;
[ii]:
X je -CRA;
RA je skupina koju prikazuje sljedeća opća formula [10]:
[image]
(gdje * ima isto značenje kao što je opisano gore; a RB predstavlja (a) amino, izborno supstituiran s jednom ili dvije skupine, koje se bira iz skupine koju čine alkil, cikloalkil, (cikloalkil)alkil i alkoksialkil, (b) alkoksi, (c) hidroksi ili (d) zasićena prstenasta amino skupina); i
R2 je H.
3. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s patentnim zahtjevom 1, naznačen time što:
X je CH;
R2 je:
(1) skupina koju prikazuje sljedeća opća formula [11]:
[image]
(gdje * ukazuje na položaj za vezanje; a RF1 i RG1 su isti ili različiti i svaki od njih predstavlja (a) H, (b) alkil, izborno supstituiran s jednom ili dvije skupine, koje se bira iz skupine koju čine hidroksi, amino, dialkilamino, zasićena prstenasta amino skupina, alkilkarbonilamino, alkilsulfonilamino, aril, heteroaril izborno supstituiran s alkilom, tetrahidrofuranil i karbamoil, (c) alkilkarbonil, (d) alkilsulfonil, (e) karbamoil ili (f) heteroaril, izborno supstituiran s alkilom, ili se alternativno RF1 i RG1 uzima zajedno sa susjednim N kako bi predstavljali zasićenu prstenastu amino skupinu, koja može biti izborno supstituirana s jednom ili dvije skupine, koje se bira iz skupine koju čine (a) halogen, (b) cijano, (c) hidroksi, (d) alkil, izborno supstituiran s jednom ili dvije skupine, koje se bira iz skupine koju čine hidroksi, alkoksi, amino, alkoksikarbonilamino, alkilsulfonilamino i alkilkarbonilamino, (e) cikloalkil, (f) haloalkil, (g) alkoksi, (h) okso, (i) skupina koju prikazuje sljedeća opća formula [4]:
[image]
(gdje * ima isto značenje kao što je opisano gore; a RH predstavlja alkil ili aril), (j) skupina koju prikazuje sljedeća opća formula [5]:
[image]
(gdje * ima isto značenje kao što je opisano gore; a RI i RJ su isti ili različiti i svaki od njih predstavlja H, alkil, karbamoil, alkilkarbonil ili alkilsulfonil), (k) skupina koju prikazuje sljedeća opća formula [6]:
[image]
(gdje * ima isto značenje kao što je opisano gore; a RK predstavlja alkil, hidroksi, amino, alkilamino, dialkilamino, cikloalkilamino, (cikloalkil)alkilamino, (hidroksialkil)amino, (alkoksialkil)amino, alkoksi, alkilsulfonilamino ili zasićenu prstenastu amino skupinu) i (l) zasićena prstenasta amino skupina, izborno supstituirana s hidroksilom,
(2) skupina koju prikazuje sljedeća opća formula [8]:
[image]
(gdje * ima isto značenje kao što je opisano gore; a RL predstavlja (a) alkil, (b) hidroksi, (c) alkoksi, (d) zasićenu prstenastu amino skupinu, izborno supstituiranu s alkilom ili alkilsulfonilom, ili (e) amino, izborno supstituiran s jednom ili dvije skupine, koje se bira iz skupine koju čine alkil, cikloalkil, (cikloalkil)alkil, aralkil, haloalkil, dialkilaminoalkil, alkoksialkil i hidroksialkil),
(3) skupina koju prikazuje sljedeća opća formula [9]:
[image]
(gdje * ima isto značenje kao što je opisano gore; a RM, RN i RO su isti ili različiti i svaki od njih predstavlja H, halogen, cijano, alkoksi, karbamoil, sulfamoil, monoalkilaminosulfonil ili alkilsulfonil, ili se alternativno dva od RM, RN i RO uzima zajedno kako bi predstavljali metilendioksi),
(4) -ORP1 (gdje RP1 predstavlja alkil, izborno supstituiran sa skupinom koju se bira iz skupine koju čine hidroksi, dialkilamino, alkoksi, tetrahidrofuranil i cikloalkil), ili
(5) heteroaril, izborno supstituiran s jednom ili dvije skupine, koje se bira iz skupine koju čine cijano, halogen, hidroksi, alkoksi, alkilkarbonil, karbamoil, alkil, cikloalkil, (cikloalkil)alkil, aralkil, hidroksikarbonil i alkoksialkil.
4. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s patentnim zahtjevom 1, naznačen time što se navedeni spoj bira iz skupine koju čine sljedeći spojevi (1) do (229):
(1) (S)-4-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}piperazin-2-on,
(2) N-{(S)-1-[2-{[(S)-1-(4-fluorfenil)etil]amino}-6-(pirazin-2-ilamino)pirimidin-4-il]pirolidin-3-il}acetamid,
(3) (S)-6-(3,3-difluorazetidin-1-il)-N2-[1-(4-fluorfenil)etil]-N4-(pirazin-2-il)pirimidin-2,4-diamin,
(4) (S)-N2-[1-(4-fluorfenil)etil]-4-(1-metil-1H-pirazol-4-il)-N6-(pirazin-2-il)piridin-2,6-diamin,
(5) (S)-N2′-[1-(4-fluorfenil)etil]-N6′-(pirazin-2-il)-3,4′-bipiridin-2′,6′-diamin,
(6) (S)-N2′-[1-(4-fluorfenil)etil]-6-metoksi-N6′-(pirazin-2-il)-3,4′-bipiridin-2′,6′-diamin,
(7) (S)-2′-[1-(4-fluorfenil)etilamino]-6′-(pirazin-2-ilamino)-3,4′-bipiridin-6-ol,
(8) (S)-N2-[1-(4-fluorfenil)etil]-4-(oksazol-5-il)-N6-(pirazin-2-il)piridin-2,6-diamin,
(9) (S)-6-chloro-N2-[1-(4-fluorfenil)etil]-N4-(pirazin-2-il)pirimidin-2,4-diamin,
(10) (S)-N2-[1-(4-fluorfenil)etil]-6-[4-(metilsulfonil)fenil]-N4-(pirazin-2-il)pirimidin-2,4-diamin,
(11) (S)-N2-[1-(4-fluorfenil)etil]-N4-(pirazin-2-il)-6-(1H-pirazol-4-il)pirimidin-2,4-diamin,
(12) (S)-2-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)piridin-4-iloksi}etanol,
(13) (S)-N2-[1-(4-fluorfenil)etil]-N4-(pirazin-2-il)-6-(piridin-3-il)pirimidin-2,4-diamin,
(14) (S)-N2-[1-(4-fluorfenil)etil]-N4-(pirazin-2-il)-6-(piridin-2-il)pirimidin-2,4-diamin,
(15) (S)-N2-[1-(4-fluorfenil)etil]-N4-(pirazin-2-il)-6-(piridin-4-il)pirimidin-2,4-diamin,
(16) (S)-1-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}pirolidin-2-on,
(17) (S)-4-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}piperazin-2,6-dion,
(18) (S)-1-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}tetrahidropirimidin-2(1H)-on,
(19) (S)-N2-[1-(4-fluorfenil)etil]-N4-(pirazin-2-il)-6-(pirolidin-1-il)pirimidin-2,4-diamin,
(20) (S)-N2-[1-(4-fluorfenil)etil]-6-morfolino-N4-(pirazin-2-il)pirimidin-2,4-diamin,
(21) (S)-1-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}imidazolidin-2-on,
(22) (S)-N2-[1-(4-fluorfenil)etil]-6-(oksazol-5-il)-N4-(pirazin-2-il)pirimidin-2,4-diamin,
(23) (S)-N2-[1-(4-fluorfenil)etil]-6-(6-methoksipiridin-3-il)-N4-(pirazin-2-il)pirimidin-2,4-diamin,
(24) (S)-N2-[1-(4-fluorfenil)etil]-N4-(pirazin-2-il)-6-(1H-pirazol-3-il)pirimidin-2,4-diamin,
(25) (S)-4-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}piridin-2-ol,
(26) (S)-5-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}piridin-2-ol,
(27) N-((R)-1-(2-[(S)-1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}pirolidin-3-il)acetamid,
(28) (S)-N2-[1-(4-fluorfenil)etil]-N6-(pirazin-2-il)-4-(1H-pirazol-4-il)piridin-2,6-diamin,
(29) (S)-N2-[1-(4-fluorfenil)etil]-N6-(pirazin-2-il)-4-(1H-pirazol-3-il)piridin-2,6-diamin,
(30) (S)-N2-[1-(4-fluorfenil)etil]-6-[3-(metilsulfonil)fenil]-N4-(pirazin-2-il)pirimidin-2,4-diamin,
(31) (S)-N2-[1-(4-fluorfenil)etil]-4-[4-(metilsulfonil)fenil]-N6-(pirazin-2-il)piridin-2,6-diamin,
(32) (S)-N2-[1-(4-fluorfenil)etil]-4-(1-izopropil-1H-pirazol-4-il)-N6-(pirazin-2-il)piridin-2,6-diamin,
(33) N-{(S)-1-[2-{[(S)-1-(4-fluorfenil)etil]amino}-6-(pirazin-2-ilamino)piridin-4-il]pirolidin-3-il}acetamid,
(34) (S)-N2-[1-(4-fluorfenil)etil]-4-morfolino-N6-(pirazin-2-il)piridin-2,6-diamin,
(35) (S)-N2-[1-(4-fluorfenil)etil]-N6-(pirazin-2-il)-4-tiomorfolinopiridin-2,6-diamin,
(36) (S)-3-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)piridin-4-il}propan-1-ol,
(37) (S)-N-(1-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}azetidin-3-il)acetamid,
(38) (S)-6-(azetidin-1-il)-N2-[1-(4-fluorfenil)etil]-N4-(pirazin-2-il)pirimidin-2,4-diamin,
(39) (S)-6-(3-fluorazetidin-1-il)-N2-[1-(4-fluorfenil)etil]-N4-(pirazin-2-il)pirimidin-2,4-diamin,
(40) (S)-1-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}azetidin-2-on,
(41) (S)-4-(1-etil-1H-pirazol-4-il)-N2-[1-(4-fluorfenil)etil]-N6-(pirazin-2-il)piridin-2,6-diamin,
(42) (S)-N2-[1-(4-fluorfenil)etil]-4-(1-metil-1H-pirazol-5-il)-N6-(pirazin-2-il)piridin-2,6-diamin,
(43) (S)-4-[1-(ciklopropilmetil)-1H-pirazol-4-il]-N2-[1-(4-fluorfenil)etil]-N6-(pirazin-2-il)piridin-2,6-diamin,
(44) (S)-N2-[1-(4-fluorfenil)etil]-N4-(pirazin-2-il)-6-(thiazol-5-il)pirimidin-2,4-diamin,
(45) 1-{2-[(S)-1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}pirolidin-3-ol,
(46) (S)-N2-[1-(4-fluorfenil)etil]-N4-(5-metilthiazol-2-il)-N6-(pirazin-2-il)pirimidin-2,4,6-triamin,
(47) (S)-N2-[1-(4-fluorfenil)etil]-N6-(pirazin-2-il)-4,5′-bipirimidin-2,6-diamin,
(48) (S)-N2-[1-(4-fluorfenil)etil]-6-(2-metoksithiazol-5-il)-N4-(pirazin-2-il)pirimidin-2,4-diamin,
(49) (S)-N2-[1-(4-fluorfenil)etil]-N4-(pirazin-2-il)-6-(thiazol-2-il)pirimidin-2,4-diamin,
(50) (S)-5-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}pikolinonitril,
(51) (S)-1-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}piperidin-4-karboksamid,
(52) (S)-5-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}pikolinamid,
(53) 4-{2-[(S)-1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}piperazine-2-karboksamid,
(54) 6-(3-aminopirolidin-1-il)-N2-[(S)-1-(4-fluorfenil)etil]-N4-(pirazin-2-il)pirimidin-2,4-diamin,
(55) N-(1-{2-[(S)-1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}pirolidin-3-il)metansulfonamid,
(56) (S)-2-({2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}(2-hidroksietil)amino)ethan-1-ol,
(57) (S)-N4-[2-(dimetilamino)etil]-N2-[1-(4-fluorfenil)etil]-N6-(pirazin-2-il)pirimidin-2,4,6-triamin,
(58) 1-{2-[(S)-1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}piperidin-3-karboksamid,
(59) (S)-1-{2-[(S)-1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}pirolidin-2-karboksamid,
(60) (S)-N2-[1-(4-fluorfenil)etil]-6-[4-(metilsulfonil)piperazin-1-il]-N4-(pirazin-2-il)pirimidin-2,4-diamin,
(61) (S)-N2-[1-(4-fluorfenil)etil]-N4-(pirazin-2-il)-6-(1H-pirol-3-il)pirimidin-2,4-diamin,
(62) (R)-1-{2-[(S)-1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}-4-hidroksipirolidin-2-on,
(63) N2-[(S)-1-(4-fluorfenil)etil]-N4-(pirazin-2-il)-N6-[(tetrahidrofuran-2-il)metil]pirimidin-2,4,6-triamin,
(64) ((S)-1-{2-[(S)-1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}pirolidin-2-il)metanol,
(65) ((R)-1-{2-[(S)-1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}pirolidin-2-il)metanol,
(66) (S)-1-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}piperidin-4-ol,
(67) (S)-1-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}azetidin-3-ol,
(68) 1-{2-[(S)-1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}piperidin-3-ol,
(69) (S)-5-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}nikotinonitril,
(70) (S)-N2-[1-(4-fluorfenil)etil]-N4-(pirazin-2-il)-6-{2H-tetrazol-5-il)pirimidin-2,4-diamin,
(71) (S)-N4-(2-aminoetil)-N2-[1-(4-fluorfenil)etil]-N6-(pirazin-2-il)pirimidin-2,4,6-triamin,
(72) (S)-N-(2-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-ilamino}etil)metansulfonamid,
(73) (S)-N-(2-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-ilamino}etil)acetamid,
(74) (S)-2-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-ilaminolacetamid,
(75) (S)-4-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}benzamid,
(76) (S)-3-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}benzonitril,
(77) (S)-N2-[1-(4-fluorfenil)etil]-6-(furan-3-il)-N4-(pirazin-2-il)pirimidin-2,4-diamin,
(78) etil-(S)-1-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}piperidin-4-karboksilat,
(79) (S)-5-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}nikotinamid,
(80) (S)-1-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}piperidin-4-karboksilna kiselina,
(81) (S)-2-{2-[(S)-1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-ilamino}-2-feniletanol,
(82) (S)-2-{2-[(S)-1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-ilamino}-3-fenilpropan-1-ol,
(83) (R)-2-{2-[(S)-1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-ilamino}-4-metilpentan-1-ol,
(84) (S)-6-[2-(dimetilamino)etoksi]-N2-[1-(4-fluorfenil)etil]-N4-(pirazin-2-il)pirimidin-2,4-diamin,
(85) (S)-1-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}-1H-pirazole-4-karboksilna kiselina,
(86) (S)-3-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}benzamid,
(87) (S)-6-(benzo[d]1,3-dioksol-5-il)-N2-[1-(4-fluorfenil)etil]-N4-(pirazin-2-il)pirimidin-2,4-diamin,
(88) (S)-N2-[1-(4-fluorfenil)etil]-6-(2-fluorpiridin-4-il)-N4-(pirazin-2-il)pirimidin-2,4-diamin,
(89) N2-[(S)-1-(4-fluorfenil)etil]-N4-(pirazin-2-il)-6-[(tetrahidrofuran-2-il)metoksi]pirimidin-2,4-diamin,
(90) (S)-2-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-iloksi}etanol,
(91) (S)-N2-[1-(4-fluorfenil)etil]-N4-(pirazin-2-il)-N6-[2-(pirolidin-1-il)etil]pirimidin-2,4,6-triamin,
(92) (S)-3-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}izonikotinamid,
(93) (S)-3-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}izonikotinonitril,
(94) (S)-2-{2-[(S)-1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-ilamino}-3-metilbutan-1-ol,
(95) (S)-N2-[1-(4-chlorofenil)etil]-6-[4-(metilsulfonil)piperazin-1-il]-N4-(pirazin-2-il)pirimidin-2,4-diamin,
(96) (1S,2S)-2-{2-[(S)-1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-iloksi}cikloheksanol,
(97) (S)-N2-[1-(4-fluorfenil)etil]-N4-[(5-metilpirazin-2-il)metil]-N6-(pirazin-2-il)pirimidin-2,4,6-triamin,
(98) (S)-N2-[1-(4-fluorfenil)etil]-N4-(furan-2-ilmetil)-N6-(pirazin-2-il)pirimidin-2,4,6-triamin,
(99) (S)-N2-[1-(4-fluorfenil)etil]-N4-(pirazin-2-il)-N6-[1-(piridin-3-il)etil]pirimidin-2,4,6-triamin,
(100) (S)-1-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}-4-(hidroksimetil)piperidin-4-ol,
(101) (S)-N2-[1-(4-fluorfenil)etil]-N4-(pirazin-2-il)-N6-(piridin-2-ilmetil)pirimidin-2,4,6-triamin,
(102) (S)-N2-[1-(4-fluorfenil)etil]-N4-(pirazin-2-il)-N6-(piridin-3-ilmetil)pirimidin-2,4,6-triamin,
(103) (S)-N2-[1-(4-fluorfenil)etil]-N4-(pirazin-2-il)-N6-(piridin-4-ilmetil)pirimidin-2,4,6-triamin,
(104) (S)-2-{2-[(S)-1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-ilamino}-3-hidroksipropanamid,
(105) (3S,4S)-1-{2-[(S)-1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}pirolidin-3,4-diol,
(106) N2-[(S)-1-(4-fluorfenil)etil]-N4-(pirazin-2-il)-6-(1,4-dioksa-8-azaspiro[4.5]dekan-8-il)pirimidin-2,4-diamin,
(107) (S)-8-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}-1,3-diokso-8-azaspiro[4.5]dekan-2-on,
(108) (S)-4-(1-benzil-1H-pirazol-4-il)-N2-[1-(4-fluorfenil)etil]-N6-(pirazin-2-il)piridin-2,6-diamin,
(109) (S)-N2-[1-(4-fluorfenil)etil]-6-[4-(fenilsulfonil)piperazin-1-il]-N4-(pirazin-2-il)pirimidin-2,4-diamin,
(110) (S)-4-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)piridin-4-il}benzamid,
(111) (S)-N2-1-(4-fluorfenil)etil]-N6-(pirazin-2-il)-4-(1H-pirol-3-il)piridin-2,6-diamin,
(112) (S)-N2-[1-(4-fluorfenil)etil]-N6-(pirazin-2-il)piridin-2,6-diamin,
(113) (S)-N2-[1-(4-fluorfenil)etil]-6-(4-metil-1H-imidazol-1-il)-N4-(pirazin-2-il)pirimidin-2,4-diamin,
(114) (S)-N2-[1-(4-fluorfenil)etil]-4-(4-methoksifenil)-N6-(pirazin-2-il)piridin-2,6-diamin,
(115) (S)-4-(4-fluorfenil)-N2-[1-(4-fluorfenil)etil]-N6-(pirazin-2-il)piridin-2,6-diamin,
(116) (S)-N2-[1-(4-fluorfenil)etil]-4-metil-N6-(pirazin-2-il)piridin-2,6-diamin,
(117) (S)-1-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}-N-(metilsulfonil)piperidin-4-karboksamid,
(118) (S)-N2-[1-(4-fluorfenil)etil]-4-(furan-3-il)-N6-(pirazin-2-il)piridin-2,6-diamin,
(119) (S)-N2-[1-(4-fluorfenil)etil]-4-[4-(metilsulfonil)piperazin-1-il]-N6-(pirazin-2-il)piridin-2,6-diamin,
(120) (S)-1-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)piridin-4-il}-4-(hidroksimetil)piperidin-4-ol,
(121) (S)-4-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)piridin-4-il}benzensulfonamid,
(122) (S)-N2-[1-(4-fluorfenil)etil]-4-metoksi-N6-(pirazin-2-il)piridin-2,6-diamin,
(123) 4-{2-[(1S)-1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)piridin-4-il}-1λ6,4-tiomorfolin-1,1-dion,
(124) (S)-1-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)piridin-4-il}piperidin-4-ol,
(125) (S)-1-(4-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)piridin-4-il}-1,4-diazepan-1-il)etanon,
(126) (S)-N2-[1-(4-fluorfenil)etil]-N6-(pirazin-2-il)-N4-(pirimidin-2-il)piridin-2,4,6-triamin,
(127) (S)-N2-[1-(4-fluorfenil)etil]-N6-(pirazin-2-il)-N4-(piridin-2-il)piridin-2,4,6-triamin,
(128) N2-[(S)-1-(4-fluorfenil)etil]-N6-(pirazin-2-il)-4-(1,4-dioksa-8-azaspiro[4.5]dekan-8-il)piridin-2,6-diamin,
(129) metil-(S)-2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)izonikotinat,
(130) (S)-4-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}-N-metilbenzensulfonamid,
(131) (S)-N2-[1-(4-fluorfenil)etil]-4-(4-metil-1H-imidazol-1-il)-N6-(pirazin-2-il)piridin-2,6-diamin,
(132) (S)-N2-[1-(4-fluorfenil)etil]-N4,N6-di(pirazin-2-il)piridin-2,4,6-triamin,
(133) (S)-4-(ciklopropilmetoksi)-N2-[1-(4-fluorfenil)etil]-N6-(pirazin-2-il)piridin-2,6-diamin,
(134) (S)-N2-[1-(4-fluorfenil)etil]-N2-metil-4-(1-metil-1H-pirazol-4-il)-N6-(pirazin-2-il)piridin-2,6-diamin,
(135) (S)-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)piridin-4-il}metanol,
(136) (S)-2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)izonikotinska kiselina,
(137) (S)-N2-[1-(4-fluorfenil)etil]-4-(2-metoksietoksi)-N6-(pirazin-2-il)piridin-2,6-diamin,
(138) (S)-2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-karbonitril,
(139) (S)-2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)izonikotinonitril,
(140) (S)-2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)izonikotinamid,
(141) (S)-N2-[1-(4-fluorfenil)etil]-6-(1,2,4-oksadiazol-3-il)-N4-(pirazin-2-il)pirimidin-2,4-diamin,
(142) (S)-N2-[1-(4-fluorfenil)etil]-4-(1,2,4-oksadiazol-3-il)-N6-(pirazin-2-il)piridin-2,6-diamin,
(143) metil-(S)-2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)nikotinat,
(144) (S)-2-[1-(4-fluorfenil)etilamino]-N,N-dimetil-6-(pirazin-2-ilamino)izonikotinamid,
(145) (S)-N-[2-(dimetilamino)etil]-2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)izonikotinamid,
(146) (S)-N-t-butil-2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)izonikotinamid,
(147) (S)-N-etil-2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)izonikotinamid,
(148) (S)-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)piridin-4-il}[4-(metansulfonil)piperazin-1-il]metanon,
(149) (S)-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)piridin-4-il}(pirolidin-1-il)metanon,
(150) (S)-2-[1-(4-fluorfenil)etilamino]-N-izopropil-6-(pirazin-2-ilamino)izonikotinamid,
(151) (S)-1-{2-[(S)-1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}azetidin-2-karboksamid,
(152) (S)-N2-[1-(4-fluorfenil)etil]-N6-(pirazin-2-il)-4-(tetrahidro-2H-piran-4-iloksi)piridin-2,6-diamin,
(153) (S)-1-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}azetidin-3-karboksamid,
(154) (S)-2-[1-(4-fluorfenil)etilamino]-N-(2-hidroksietil)-6-(pirazin-2-ilamino)izonikotinamid,
(155) (S)-2-[1-(4-fluorfenil)etilamino]-N-metil-6-(pirazin-2-ilamino)izonikotinamid,
(156) (S)-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)piridin-4-il}(morfolino)metanon,
(157) (S)-N-benzil-2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)izonikotinamid,
(158) (S)-N-ciklopropil-2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)izonikotinamid,
(159) (S)-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)piridin-4-il}(4-metilpiperazin-1-il)metanon,
(160) (S)-2-[1-(4-fluorfenil)etilamino]-N-(2-metoksietil)-6-(pirazin-2-ilamino)izonikotinamid,
(161) (S)-2-[1-(4-fluorfenil)etilamino]-N-propil-6-(pirazin-2-ilamino)izonikotinamid,
(162) (S)-N-ciklopropilmetil-2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)izonikotinamid,
(163) (S)-N-ciklobutil-2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)izonikotinamid,
(164) (S)-N-butil-2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)izonikotinamid,
(165) (S)-2-[1-(4-fluorfenil)etilamino]-N-izobutil-6-(pirazin-2-ilamino)izonikotinamid,
(166) (S)-2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)-N-(2,2,2-trifluoretil)izonikotinamid,
(167) (S)-2-[1-(4-fluorfenil)etilamino]-N-(3-hidroksipropil)-6-(pirazin-2-ilamino)izonikotinamid,
(168) (S)-N-(2-etoksietil)-2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)izonikotinamid,
(169) (S)-1-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}-N-metilazetidin-3-karboksamid,
(170) (S)-N2-[1-(4-fluorfenil)etil]-4-(metoksimetil)-N6-(pirazin-2-il)piridin-2,6-diamin,
(171) (S)-1-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}-N,N-dimetilazetidin-3-karboksamid,
(172) (S)-N-(1-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}azetidin-3-il)metansulfonamid,
(173) (S)-1-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}azetidin-3-karbonitril,
(174) 2-(4-fluorfenil)-2-[4-(1-metil-1H-pirazol-4-il)-6-(pirazin-2-ilamino)piridin-2-ilamino]etanol,
(175) (S)-N-etil-1-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}azetidin-3-karboksamid,
(176) (S)-N,N-dietil-1-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}azetidin-3-karboksamid,
(177) (S)-1-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)piridin-4-il}etanon,
(178) (S)-N2-[1-(4-fluorfenil)etil]-6-(3-metoksiazetidin-1-il)-N4-(pirazin-2-il)pirimidin-2,4-diamin,
(179) (S)-1-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}-3-metilazetidin-3-ol,
(180) (S)-2-[1-(4-fluorfenil)etilamino]-N-metil-6-(pirazin-2-ilamino)nikotinamid,
(181) (S)-2-[1-(4-fluorfenil)etilamino]-N,N-dimetil-6-(pirazin-2-ilamino)nikotinamid,
(182) (S)-2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)nikotinamid,
(183) (S)-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)piridin-3-il}(morfolino)metanon,
(184) (S)-N-(ciklopropilmetil)-2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)nikotinamid,
(185) (S)-N-(1-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}azetidin-3-il)etansulfonamid,
(186) (S)-1-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}-N-izopropilazetidin-3-karboksamid,
(187) (S)-1-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}-3-(trifluormetil)azetidin-3-ol,
(188) (S)-(1-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}azetidin-3-il)(pirolidin-1-il)metanon,
(189) (S)-1-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}-N-(2-metoksietil)azetidin-3-karboksamid,
(190) (S)-(1-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}azetidin-3-il)(piperidin-1-il)metanon,
(191) (S)-(1-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}azetidin-3-il)(morfolino)metanon,
(192) (S)-N-(ciklopropil)-1-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}azetidin-3-karboksamid,
(193) (S)-N-(ciklopropilmetil)-1-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}azetidin-3-karboksamid,
(194) (S)-1-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}-N-(2-hidroksietil)azetidin-3-karboksamid,
(195) (S)-3-ciklopropil-1-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}azetidin-3-ol,
(196) (S)-1-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}-3-izopropilazetidin-3-ol,
(197) (S)-1-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)piridin-4-il}azetidin-3-ol,
(198) (S)-3-ciklopropil-1-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)piridin-4-il}azetidin-3-ol,
(199) (S)-1-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)piridin-4-il}-3-izopropilazetidin-3-ol,
(200) (S)-1-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)piridin-4-il}-3-metilazetidin-3-ol,
(201) (S)-1-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)piridin-4-il}-3-(trifluormetil)azetidin-3-ol,
(202) (S)-4-(3,3-difluorazetidin-1-il)-N2-[1-(4-fluorfenil)etil]-N6-(pirazin-2-il)piridin-2,6-diamin,
(203) (S)-N-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)piridin-4-il}acetamid,
(204) (S)-N-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)piridin-4-il}metansulfonamid,
(205) (S)-1-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)piridin-4-il}urea,
(206) (S)-4-(3-ciklopropil-3-metoksiazetidin-1-il)-N2-[1-(4-fluorfenil)etil]-N6-(pirazin-2-il)piridin-2,6-diamin,
(207) (S)-N2-[1-(4-fluorfenil)etil]-4-(3-izopropil-3-metoksiazetidin-1-il)-N6-(pirazin-2-il)piridin-2,6-diamin,
(208) (S)-N2-[1-(4-fluorfenil)etil]-4-(3-metoksi-3-metilazetidin-1-il)-N6-(pirazin-2-il)piridin-2,6-diamin,
(209) (S)-N2-[1-(4-fluorfenil)etil]-4-(1-metil-1H-pirazol-4-il)-N6-(5-metilpirazin-2-il)piridin-2,6-diamin,
(210) (S)-N2-[1-(4-fluorfenil)etil]-4-[1-(metansulfonil)piperidin-4-il]-N6-(pirazin-2-il)piridin-2,6-diamin,
(211) (S)-N-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)piridin-4-il}propionamid,
(212) (S)-N2-[1-{4-fluorfenil)etil]-4-[1-(2-metoksietil)-1H-pirazol-4-il]-N6-(pirazin-2-il)piridin-2,6-diamin,
(213) (S)-4-(1-ciklopropil-1H-pirazol-4-il)-N2-[1-(4-fluorfenil)etil]-N6-(pirazin-2-il)piridin-2,6-diamin,
(214) (S)-N2-[1-(4-fluorfenil)etil]-4-[1-(metoksimetil)-1H-pirazol-4-il]-N6-(pirazin-2-il)piridin-2,6-diamin,
(215) (S)-6-[3-(dimetilamino)azetidin-1-il]-N2-[1-(4-fluorfenil)etil]-N4-(pirazin-2-il)pirimidin-2,4-diamin,
(216) (S)-N2-[1-(4-fluorfenil)etil]-6-[3-(metilamino)azetidin-1-il]-N4-(pirazin-2-il)pirimidin-2,4-diamin,
(217) (S)-N2-[1-(4-fluorfenil)etil]-N4-(pirazin-2-il)-6-[3-(pirolidin-1-il)azetidin-1-il]pirimidin-2,4-diamin,
(218) (S)-N2-[1-(4-fluorfenil)etil]-6-(3-morfolinoazetidin-1-il)-N4-(pirazin-2-il)pirimidin-2,4-diamin,
(219) (S)-N2-[1-(4-fluorfenil)etil]-6-[3-(4-metilpiperazin-1-il)azetidin-1-il]-N4-(pirazin-2-il)pirimidin-2,4-diamin,
(220) (S)-(1-{1-[2-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}azetidin-3-il)piperidin-4-ol,
(221) 4-{2-[(1S)-1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}-1λ6,4-tiomorfolin-1,1-dion,
(222) (S)-1-(1-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}azetidin-3-il)urea,
(223) (S)-(1-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}azetidin-3-il)metanol,
(224) t-butil-(S)-(1-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}azetidin-3-il)metilkarbamat,
(225) (S)-6-[3-(aminometil)azetidin-1-il]-N2-[1-(4-fluorfenil)etil]-N4-(pirazin-2-il)pirimidin-2,4-diamin,
(226) (S)-N-[(1-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}azetidin-3-il)metil]etansulfonamid,
(227) (S)-N-[(1-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)pirimidin-4-il}azetidin-3-il)metil]acetamid,
(228) (S)-N2-[1-(4-fluorfenil)etil]-4-[3-morfolinoazetidin-1-il]-N6-(pirazin-2-il)piridin-2,6-diamin, te
(229) (S)-1-(1-{2-[1-(4-fluorfenil)etilamino]-6-(pirazin-2-ilamino)piridin-4-il}azetidin-3-il)piperidin-4-ol.
5. Farmaceutski pripravak, naznačen time što sadrži spoj, ili njegovu farmaceutski prihvatljivu sol, u skladu s bilo kojim od patentnih zahtjeva 1 do 4 kao aktivni sastojak.
6. Farmaceutski pripravak u skladu s patentnim zahtjevom 5, naznačen time što je namijenjen upotrebi u sprječavanju ili liječenju raka, upalnog poremećaja ili angiopatije.
7. Farmaceutski pripravak u skladu s patentnim zahtjevom 6, naznačen time što rak je rak krvi ili čvrsti oblik raka.
8. Farmaceutski pripravak u skladu s patentnim zahtjevom 7, naznačen time što je rak krvi mijeloidna proliferativna novotvorina, mijelodisplastični sindromi, akutna limfocitna leukemija, akutna mijeloidna leukemija, kronična mijeloidna leukemija ili multipli mijelom.
9. Farmaceutski pripravak u skladu s patentnim zahtjevom 8, naznačen time što je mijeloidna proliferativna novotvorina policitemija vera.
10. Farmaceutski pripravak u skladu s patentnim zahtjevom 8, naznačen time što je mijeloidna proliferativna novotvorina esencijalna trombocitemija.
11. Farmaceutski pripravak u skladu s patentnim zahtjevom 8, naznačen time što je mijeloidna proliferativna novotvorina idiopatska mijelofibroza.
12. Farmaceutski pripravak u skladu s patentnim zahtjevom 7, naznačen time što je čvrsti oblik raka rak prostate ili rak dojke.
13. Farmaceutski pripravak u skladu s patentnim zahtjevom 6, naznačen time što je upalni poremećaj reumatoidni artritis, upalna bolest crijeva, osteoporoza ili multipla skleroza.
14. Farmaceutski pripravak u skladu s patentnim zahtjevom 6, naznačen time što je angiopatija plućna hipertenzija, arterioskleroza, aneurizma ili varikozna vena.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009026470 | 2009-02-06 | ||
JP2009276133 | 2009-12-04 | ||
PCT/JP2010/051722 WO2010090290A1 (ja) | 2009-02-06 | 2010-02-05 | アミノピラジン誘導体及び医薬 |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20140265T1 true HRP20140265T1 (hr) | 2014-04-25 |
Family
ID=42542181
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20140265AT HRP20140265T1 (hr) | 2009-02-06 | 2014-03-20 | Derivat aminopirazina i odgovarajuä†i lijek |
Country Status (19)
Country | Link |
---|---|
US (2) | US8673891B2 (hr) |
EP (1) | EP2394999B1 (hr) |
JP (1) | JP5263304B2 (hr) |
KR (1) | KR101677778B1 (hr) |
CN (1) | CN102307869B (hr) |
AU (1) | AU2010211672B2 (hr) |
BR (1) | BRPI1008661B8 (hr) |
CA (1) | CA2751695C (hr) |
DK (1) | DK2394999T3 (hr) |
ES (1) | ES2453474T3 (hr) |
HR (1) | HRP20140265T1 (hr) |
MX (1) | MX2011008243A (hr) |
MY (1) | MY155374A (hr) |
PL (1) | PL2394999T3 (hr) |
PT (1) | PT2394999E (hr) |
RU (1) | RU2535217C2 (hr) |
SI (1) | SI2394999T1 (hr) |
WO (1) | WO2010090290A1 (hr) |
ZA (1) | ZA201105623B (hr) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2394999B1 (en) * | 2009-02-06 | 2014-01-29 | Nippon Shinyaku Co., Ltd. | Aminopyrazine derivative and medicine |
US20120121515A1 (en) | 2009-03-13 | 2012-05-17 | Lenny Dang | Methods and compositions for cell-proliferation-related disorders |
ES2632954T3 (es) | 2009-06-29 | 2017-09-18 | Agios Pharmaceuticals, Inc. | Derivados de quinolina-8-sulfonamida que tienen una actividad anticancerosa |
WO2011050210A1 (en) | 2009-10-21 | 2011-04-28 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
WO2012005299A1 (ja) * | 2010-07-07 | 2012-01-12 | 日本新薬株式会社 | Rosチロシンキナーゼ阻害剤 |
JP5668756B2 (ja) * | 2010-08-11 | 2015-02-12 | 日本新薬株式会社 | 悪性リンパ腫治療剤 |
WO2012020786A1 (ja) * | 2010-08-11 | 2012-02-16 | 日本新薬株式会社 | 医薬組成物 |
EP2702055A1 (en) * | 2011-04-11 | 2014-03-05 | Nerviano Medical Sciences S.r.l. | Pyrazolyl-pyrimidine derivatives as kinase inhibitors |
SG194697A1 (en) | 2011-05-03 | 2013-12-30 | Agios Pharmaceuticals Inc | Pyruvate kinase activators for use in therapy |
CN102827073A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
CN102827170A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
WO2013004332A1 (en) * | 2011-07-07 | 2013-01-10 | Merck Patent Gmbh | Substituted azaheterocycles for the treatment of cancer |
EP2554544A1 (en) * | 2011-08-01 | 2013-02-06 | Almirall, S.A. | Pyridin-2(1h)-one derivatives as jak inhibitors |
AU2012313888B2 (en) * | 2011-09-27 | 2016-03-31 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH |
CN115536635A (zh) | 2012-01-06 | 2022-12-30 | 法国施维雅药厂 | 治疗活性化合物及其使用方法 |
US9474779B2 (en) | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
UY34632A (es) | 2012-02-24 | 2013-05-31 | Novartis Ag | Compuestos de oxazolidin- 2- ona y usos de los mismos |
EP2832734A4 (en) | 2012-03-28 | 2015-08-26 | Takeda Pharmaceutical | HETEROCYCLIC CONNECTION |
EP2906212A4 (en) | 2012-10-15 | 2016-06-08 | Agios Pharmaceuticals Inc | THERAPEUTIC COMPOUNDS AND COMPOSITIONS |
WO2014060381A1 (de) | 2012-10-18 | 2014-04-24 | Bayer Cropscience Ag | Heterocyclische verbindungen als schädlingsbekämpfungsmittel |
EP2914587A1 (de) | 2012-10-31 | 2015-09-09 | Bayer CropScience AG | Neue heterocylische verbindungen als schädlingsbekämpfungsmittel |
US9296733B2 (en) | 2012-11-12 | 2016-03-29 | Novartis Ag | Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases |
US9834520B2 (en) | 2013-03-14 | 2017-12-05 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
AP2015008707A0 (en) | 2013-03-14 | 2015-09-30 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
US20160039802A1 (en) * | 2013-03-14 | 2016-02-11 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
WO2014147586A1 (en) * | 2013-03-22 | 2014-09-25 | Novartis Ag | 1-(2-(ethylamino)pyrimidin-4-yl)pyrrolidin-2-ones as inhibitors of mutant idh |
JP6427491B2 (ja) | 2013-07-03 | 2018-11-21 | 武田薬品工業株式会社 | 複素環化合物 |
ES2950424T3 (es) | 2013-07-03 | 2023-10-09 | Takeda Pharmaceuticals Co | Compuesto de amida |
US9579324B2 (en) | 2013-07-11 | 2017-02-28 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
WO2015003355A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
EP3019480B1 (en) | 2013-07-11 | 2020-05-06 | Agios Pharmaceuticals, Inc. | 2,4- or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer |
WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
CN105492435B (zh) | 2013-07-11 | 2018-06-29 | 安吉奥斯医药品有限公司 | 作为idh2突变体抑制剂的化合物 |
US20150031627A1 (en) | 2013-07-25 | 2015-01-29 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
US20160159773A1 (en) | 2013-07-30 | 2016-06-09 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
AU2014334040A1 (en) | 2013-10-07 | 2016-04-28 | Bayer Pharma Aktiengesellschaft | Cyclic thienouracil-carboxamides and use thereof |
KR20240010105A (ko) | 2014-03-14 | 2024-01-23 | 아지오스 파마슈티컬스 아이엔씨. | 치료적으로 활성인 화합물의 약제학적 조성물 |
WO2016024231A1 (en) | 2014-08-11 | 2016-02-18 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor and/or a pd-l1 inhibitor |
PL3179991T3 (pl) | 2014-08-11 | 2022-02-14 | Acerta Pharma B.V. | Kombinacje terapeutyczne inhibitora btk i inhibitora bcl-2 |
WO2016024232A1 (en) | 2014-08-11 | 2016-02-18 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor and/or a cdk 4/6 inhibitor |
JP2017214291A (ja) * | 2014-10-09 | 2017-12-07 | 国立大学法人 宮崎大学 | 骨髄線維化の抑制剤 |
EP3307702A4 (en) * | 2015-06-11 | 2019-02-13 | University of Pittsburgh - Of the Commonwealth System of Higher Education | CHEMICAL P62 ZZ HEMMER |
US11234976B2 (en) | 2015-06-11 | 2022-02-01 | Agios Pharmaceuticals, Inc. | Methods of using pyruvate kinase activators |
US10653710B2 (en) | 2015-10-15 | 2020-05-19 | Agios Pharmaceuticals, Inc. | Combination therapy for treating malignancies |
CA3216701A1 (en) | 2015-10-15 | 2017-04-20 | Les Laboratoires Servier | Combination therapy for treating malignancies |
WO2018005533A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Antiproliferative pyrimidine-based compounds |
CN111132971A (zh) | 2017-09-28 | 2020-05-08 | 日本新药株式会社 | 晶体 |
US10980788B2 (en) | 2018-06-08 | 2021-04-20 | Agios Pharmaceuticals, Inc. | Therapy for treating malignancies |
WO2020256739A1 (en) | 2019-06-21 | 2020-12-24 | Constellation Pharmaceuticals, Inc. | Methods of treating myeloproliferative disorders |
WO2021091535A1 (en) | 2019-11-05 | 2021-05-14 | Constellation Pharmaceuticals, Inc. | Treating myeloproliferative disorders with cpi-0610 and a jak inhibitor |
WO2020257644A1 (en) | 2019-06-21 | 2020-12-24 | Constellation Pharmaceuticals, Inc. | Methods of treating myeloproliferative disorders |
WO2023175932A1 (ja) * | 2022-03-18 | 2023-09-21 | 日本新薬株式会社 | 高リスク骨髄線維症の治療剤 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA58494C2 (uk) * | 1995-06-07 | 2003-08-15 | Зенека Лімітед | Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну |
WO2000071536A1 (en) * | 1999-05-20 | 2000-11-30 | E.I. Du Pont De Nemours And Company | Heteroaryloxypyrimidine insecticides and acaricides |
DE60006541D1 (de) * | 1999-06-30 | 2003-12-18 | Merck & Co Inc | Src-kinase hemmende verbindungen |
WO2001062900A1 (en) * | 2000-02-25 | 2001-08-30 | The Regents Of The University Of California. | Scytonemin and methods of using thereof |
AU2003284399A1 (en) * | 2002-11-14 | 2004-06-03 | Kyowa Hakko Kogyo Co., Ltd. | Plk inhibitors |
WO2005049602A1 (en) | 2003-11-18 | 2005-06-02 | Warner-Lambert Company Llc | Quinolone antibacterial agents |
GB0512324D0 (en) * | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
ES2270715B1 (es) | 2005-07-29 | 2008-04-01 | Laboratorios Almirall S.A. | Nuevos derivados de pirazina. |
CN101273039A (zh) | 2005-08-12 | 2008-09-24 | 默克公司 | 可用作p38激酶抑制剂的杂二环化合物 |
WO2007140200A2 (en) | 2006-05-25 | 2007-12-06 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors |
WO2009017838A2 (en) * | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
CA2720946C (en) * | 2008-04-07 | 2013-05-28 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
EP2394999B1 (en) * | 2009-02-06 | 2014-01-29 | Nippon Shinyaku Co., Ltd. | Aminopyrazine derivative and medicine |
-
2010
- 2010-02-05 EP EP10738621.1A patent/EP2394999B1/en active Active
- 2010-02-05 MX MX2011008243A patent/MX2011008243A/es active IP Right Grant
- 2010-02-05 DK DK10738621.1T patent/DK2394999T3/da active
- 2010-02-05 PL PL10738621T patent/PL2394999T3/pl unknown
- 2010-02-05 US US13/147,001 patent/US8673891B2/en active Active
- 2010-02-05 MY MYPI2011003643A patent/MY155374A/en unknown
- 2010-02-05 BR BRPI1008661A patent/BRPI1008661B8/pt active IP Right Grant
- 2010-02-05 ES ES10738621.1T patent/ES2453474T3/es active Active
- 2010-02-05 AU AU2010211672A patent/AU2010211672B2/en active Active
- 2010-02-05 SI SI201030584T patent/SI2394999T1/sl unknown
- 2010-02-05 CA CA2751695A patent/CA2751695C/en active Active
- 2010-02-05 KR KR1020117020565A patent/KR101677778B1/ko active IP Right Grant
- 2010-02-05 CN CN201080007190.XA patent/CN102307869B/zh active Active
- 2010-02-05 PT PT107386211T patent/PT2394999E/pt unknown
- 2010-02-05 JP JP2010549525A patent/JP5263304B2/ja active Active
- 2010-02-05 WO PCT/JP2010/051722 patent/WO2010090290A1/ja active Application Filing
- 2010-02-05 RU RU2011136825/04A patent/RU2535217C2/ru active
-
2011
- 2011-07-29 ZA ZA2011/05623A patent/ZA201105623B/en unknown
-
2013
- 2013-01-17 US US13/743,550 patent/US8586591B2/en active Active
-
2014
- 2014-03-20 HR HRP20140265AT patent/HRP20140265T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
EP2394999A1 (en) | 2011-12-14 |
BRPI1008661B1 (pt) | 2020-09-15 |
SI2394999T1 (sl) | 2014-05-30 |
ZA201105623B (en) | 2012-07-25 |
WO2010090290A1 (ja) | 2010-08-12 |
EP2394999B1 (en) | 2014-01-29 |
MX2011008243A (es) | 2011-08-17 |
JPWO2010090290A1 (ja) | 2012-08-09 |
AU2010211672B2 (en) | 2016-08-04 |
CA2751695C (en) | 2017-11-28 |
ES2453474T3 (es) | 2014-04-07 |
US8586591B2 (en) | 2013-11-19 |
CN102307869A (zh) | 2012-01-04 |
BRPI1008661B8 (pt) | 2021-05-25 |
MY155374A (en) | 2015-10-15 |
BRPI1008661A2 (pt) | 2016-03-08 |
RU2011136825A (ru) | 2013-03-20 |
CN102307869B (zh) | 2014-10-22 |
US8673891B2 (en) | 2014-03-18 |
US20130131082A1 (en) | 2013-05-23 |
AU2010211672A1 (en) | 2011-08-25 |
KR101677778B1 (ko) | 2016-11-18 |
EP2394999A4 (en) | 2012-10-10 |
JP5263304B2 (ja) | 2013-08-14 |
DK2394999T3 (da) | 2014-05-05 |
PL2394999T3 (pl) | 2014-06-30 |
PT2394999E (pt) | 2014-05-02 |
RU2535217C2 (ru) | 2014-12-10 |
KR20110120932A (ko) | 2011-11-04 |
CA2751695A1 (en) | 2010-08-12 |
US20110288065A1 (en) | 2011-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20140265T1 (hr) | Derivat aminopirazina i odgovarajuä†i lijek | |
HRP20180384T1 (hr) | Derivati 2,3-dihidro-benzo[1,4]oksazina i odgovarajući spojevi kao inhibitori kinaze fosfoinozitida-3 (pi3k) za liječenje primjerice reumatoidnog artritisa | |
RU2484091C2 (ru) | Производные изоксазоло-пиридина | |
JP2015500332A5 (hr) | ||
HRP20171913T1 (hr) | Aminopirimidinilni spojevi kao inhibitori jak | |
HRP20140778T1 (hr) | Derivati tetrahidro-pirido-pirimidina | |
JP2014521711A5 (hr) | ||
RU2018123825A (ru) | Соединения и способы для модуляции киназ, и показания для этого | |
RU2005122932A (ru) | Производные бензазепина для лечения неврологических нарушений | |
CA2785113A1 (en) | Imidazopyridine derivatives as jak inhibitors | |
WO2012020786A1 (ja) | 医薬組成物 | |
RU2014149684A (ru) | Производные аминохиназолина и пиридопиримидина | |
SI2790705T1 (en) | Use of activity inhibitors or PI3K function | |
HRP20120457T1 (hr) | 4-(4-cijano-2-tioaril)dihidropirimidinoni i njihova uporaba | |
HRP20201430T1 (hr) | Spojevi 6-heterociklil-4-morfolin-4-ilpiridin-2-ona korisni za liječenje karcinoma i dijabetesa | |
RU2014131707A (ru) | Соединения пиридазинамида и их применение в качестве ингибиторов тирозинкиназы селезенки (syk) | |
RU2007106042A (ru) | Замещенные биарильные аналоги пиперазинилпиридина | |
JP2016528298A5 (hr) | ||
JP2014501269A5 (hr) | ||
JP5668756B2 (ja) | 悪性リンパ腫治療剤 | |
RU2018131775A (ru) | 6-арил-4-морфолин-1-илпиридоны, пригодные для лечения рака или диабета | |
HRP20221454T1 (hr) | Piridinamin-piridonski i pirimidinamin-piridonski spojevi | |
WO2012005299A1 (ja) | Rosチロシンキナーゼ阻害剤 | |
HRP20211999T1 (hr) | Spojevi azaindolilpiridona i diazaindolilpiridona | |
WO2023175932A1 (ja) | 高リスク骨髄線維症の治療剤 |